Canopy Growth Corporation (CGC)

Load up now.. Run to $3 incoming.

50 Bullish Reasons to Be Super Bullish on $CGC
(Each bullet begins with a Guided Link, per your formatting rules.)

Global cannabis leadership — CGC remains one of the most recognized cannabis brands worldwide.

Canadian market scale — Canada is a federally legal market with long-term growth potential.

U.S. optionality — CGC has strategic exposure to the U.S. market through structure and partnerships.

Federal reform potential — Any U.S. reform (SAFE, rescheduling) could unlock massive upside.

Rescheduling momentum — U.S. rescheduling would lower taxes and boost profitability for the sector.

Brand portfolio strength — CGC owns multiple well-known cannabis and wellness brands.

Premium product positioning — Focus on higher-margin premium flower and extracts.

Medical cannabis expansion — Growing global demand for medical cannabis treatments.

International footprint — Presence in Canada, U.S., Germany, U.K., and other markets.

Germany legalization tailwind — Germany’s evolving cannabis laws could boost CGC’s European business.

European medical dominance — Europe is one of the fastest-growing medical cannabis markets.

Strong distribution channels — CGC products reach thousands of retail locations.

High-quality cultivation — Known for consistent, high-grade cultivation standards.

Cost-cutting progress — Major restructuring has reduced operating expenses.

Path to profitability — Leaner operations improve long-term margin potential.

Balance sheet improvement — Debt reduction and restructuring efforts underway.

Strategic partnerships — Collaborations with major companies across sectors.

Consumer packaged goods strategy — CGC aims to be a global CPG cannabis powerhouse.

Innovation pipeline — New product formats, beverages, edibles, and vapes.

Cannabis beverages — Infused beverages are a fast-growing category.

Health and wellness products — CBD and wellness lines expand non-THC revenue.

CBD market potential — Global CBD demand continues to rise.

Brand loyalty — Strong consumer loyalty in multiple product categories.

Retail expansion opportunities — Potential to expand retail presence in legal markets.

U.S. state-level growth — More U.S. states legalizing cannabis each year.

Cross-border synergies — Canada-U.S. integration could unlock efficiencies.

Global legalization trend — More countries moving toward legalization.

Institutional interest potential — U.S. reform could open the door to institutional capital.

Banking reform upside — SAFE Banking would reduce costs and improve access to capital.

Lower tax burden potential — Rescheduling could eliminate 280E taxes for U.S. operators.

Supply chain optimization — Streamlined operations improve margins.

Growing export markets — Export opportunities to Europe, Australia, and Latin America.

Pharmaceutical applications — Cannabis-based medicines are a long-term growth area.

IP and research assets — CGC has invested heavily in R&D and proprietary formulations.

Veterans medical programs — Growing acceptance of cannabis for PTSD and chronic pain.

Chronic pain market — Cannabis is increasingly used as an opioid alternative.

Mental health applications — Research into anxiety, sleep, and mood disorders.

Athlete partnerships — Sports leagues warming to cannabis and CBD.

Brand diversification — Multiple brands across price tiers and product types.

E-commerce opportunities — Online cannabis sales expanding in legal markets.

Vape category growth — Vapes remain one of the fastest-growing segments.

Edibles category growth — Edibles continue to gain market share.

Concentrates demand — High-potency products have strong consumer demand.

Tourism-driven sales — Cannabis tourism boosts sales in legal regions.

Sustainability initiatives — Eco-friendly cultivation appeals to ESG investors.

ESG investment potential — Cannabis aligns with wellness and sustainability themes.

Long-term demographic tailwinds — Younger generations overwhelmingly support legalization.

Shift from illicit to legal — Legal markets continue to capture illicit market share.

Massive total addressable market — Global cannabis TAM projected to reach tens of billions.

High-risk, high-reward upside — CGC is a leveraged play on global cannabis legalization. $WEED

Canopy Growth Announces Claybourne’s Frosted Flyers Wins ‘Best Infused Pre-Roll' at 2026 Grow Up AwardsJune 8, 2026 7:30 AM
Business Wire Claybourne extends its market share momentum with expanded Frosted Flyers lineup One of Canada’s fastest-growing cannabis brands adds new variety formats built for flavour, discovery and summer pre-roll season Canopy Growth Corporation (“Canopy Growth” or the “Company”) (TSX: WEED) (Nasdaq: CGC) today announced that Claybourne’s Frosted Flyers Variety Pack has been awarded Best Infused Pre-Roll at the 2026 Grow Up Awards, presented during the annual Grow Up Conference & Expo in Toronto. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260608930080/en/Frosted Flyers Variety Pack Building on that recognition, the Company also announced the expansion of Claybourne’s Frosted Flyers infused pre-roll lineup in Canada, with three new 8-pack variety formats and the brand’s first bundle pack. “Winning Best Infused Pre-Roll at Grow Up is a clear signal that consumers and the industry are responding to what Claybourne is building in Canada,” said Luc Mongeau, Chief Executive Officer, Canopy Growth. “Frosted Flyers was designed to bring more flavour and energy to the infused pre-roll category, and this recognition tells us we’re delivering on that. Today’s expansion extends our market share momentum, giving consumers more ways to discover the brand and more reasons to reach for Claybourne this summer.” The expanded Frosted Flyers infused pre-roll lineup includes: Frosted Flyers Podium Pack | 8x0.35g | Eight flavours, eight pre-rolls, one variety pack Frosted Flyers Fast Pack | 8x0.35g | Four sativa flavours, eight pre-rolls, two of each flavour Frosted Flyers Drag Pack | 8x0.35g | Four indica flavours, eight pre-rolls, two of each flavour Frosted Flyers Variety Bundle Pack | 2x5x0.5g | Five flavours, 10 pre-rolls, one cost-effective bundle pack With the addition of the Podium Pack, Fast Pack, Drag Pack, and Variety Bundle Pack, Claybourne is extending its position in multi-pack formats while meeting growing consumer demand for variety and convenience – expanding at a key seasonal moment. “‘Built on Variety’ started as a product idea and has since evolved into a core part of our product identity,” said Jonathan Griffith, Co-Founder and VP of Marketing at Claybourne Co. “Consumers want options, and they want products that fit different occasions. These new 8x0.35g Podium, Fast and Drag packs build on that momentum with quicker sessions, more flavour rotation and curated experiences designed around how people actually consume.” Availability The new Frosted Flyers variety packs are now rolling out at select retail stores across Canada, with all formats available this summer. About Canopy Growth Canopy Growth is a world-leading cannabis company dedicated to unleashing the power of cannabis to improve lives. Its portfolio of owned and licensed brands including Tweed, 7ACRES, DOJA, Deep Space, Deelish, Claybourne, MTL Cannabis, Low Key by MTL and R’belle, as well as category defining Storz & Bickel, delivers innovative products to consumers across Canada and beyond. Canopy Growth is one of Canada’s leading providers of medical cannabis services through Canada House Clinics and serves patients online via Abba Medix. The Company also holds an unconsolidated, non-controlling interest in Canopy USA, LLC, which provides exposure to the U.S. THC market. Committed to quality, responsible use, and community, Canopy Growth is shaping a future where cannabis is embraced for its potential to enhance well-being. For more information visit www.canopygrowth.com View source version on businesswire.com: https://www.businesswire.com/news/home/20260608930080/en/ Media Contact: media@canopygrowth.com
Investor Contact: invest@canopygrowth.com Original: Canopy Growth Announces Claybourne’s Frosted Flyers Wins ‘Best Infused Pre-Roll' at 2026 Grow Up Awards

Canopy Growth Relaunches Tweed Brand in Germany with New MTL Cannabis Strain Lineup, Marking First International Release following AcquisitionMay 29, 2026 7:00 AM
Business Wire Pablo’s Revenge, Dante’z Inferno, and Frost’d Flakes launched under Tweed brand Up to five additional strains expected to follow in June 2026 Company targeting rapid growth in Germany’s medical cannabis market Canopy Growth Corporation (“Canopy Growth” or the “Company”) (TSX: WEED) (Nasdaq: CGC) today announced the relaunch of the Tweed brand in the German medical market, alongside the introduction of three cannabis strains developed by MTL Cannabis Corp. (“MTL”), a wholly-owned subsidiary of the Company. The dual milestone represents the Company’s first international product release following its recent acquisition of MTL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260529712694/en/Pablo's Revenge The Tweed brand relaunch – now powered by MTL’s premium genetics – signals the Company’s commitment to leveraging the full equity of its legacy brand in key international markets and comes as Germany’s medical cannabis market continues to expand rapidly, approaching $1 billion in annual value in 20251. The MTL acquisition has enhanced Canopy Growth’s capacity to meet rising demand in key international markets, including Germany, while reintroducing a brand that physicians and patients have come to trust. "Germany is one of the fastest-growing medical cannabis markets globally, and demand continues to scale rapidly. The relaunch of our Tweed brand is a meaningful moment for us, reflecting both the strength of what we have built, and our commitment to delivering consistent, high-quality cannabis that physicians can prescribe with confidence and patients can rely on as part of their care. We believe the European Union represents a tremendous opportunity for Canopy, and Germany is just the beginning,” said Luc Mongeau, Chief Executive Officer, Canopy Growth. The initial launch includes three cultivars – Pablo’s Revenge, Dante’z Inferno, and Frost’d Flakes – selected for their quality and consistency. Up to five MTL-derived strains are expected to be introduced in June 2026, with further portfolio expansion planned throughout the year. The Company also announced today that it has been granted a management cease trade order effective as of May 28, 2026, by its principal regulator, the Ontario Securities Commission under National Policy 12-203 – Management Cease Trade Orders. This follows the Company’s announcement on May 15, 2026 regarding certain non-cash technical errors in the Company’s accounting relating to certain share-settled warrants of the Company with exercise prices denominated in U.S. dollars, first issued during the fiscal year ended March 31, 2024. The Company intends to refile the relevant financial statements (the “Refiling”) in its Annual Report on Form 10-K for the fiscal year ended March 31, 2026, which is expected to be filed with Canadian securities regulators and with the United States Securities and Exchange Commission (the “SEC”) on June 15, 2026 (the “Comprehensive Form 10-K”). About Canopy Growth Canopy Growth is a world-leading cannabis company dedicated to unleashing the power of cannabis to improve lives. Its portfolio of owned and licensed brands including Tweed, 7ACRES, DOJA, Deep Space, Deelish, Claybourne, MTL Cannabis, Low Key by MTL and R’belle, as well as category defining Storz & Bickel, delivers innovative products to consumers across Canada and beyond. Canopy Growth is Canada’s leading provider of medical cannabis services through Canada House Clinics and serves patients online via Abba Medix. The Company also holds unconsolidated, non-controlling interest in Canopy USA, LLC, which provides exposure to the U.S. THC market. Committed to quality, responsible use, and community, Canopy Growth is shaping a future where cannabis is embraced for its potential to enhance well-being. For more information visit www.canopygrowth.com Forward-Looking Statements This news release contains “forward-looking statements” within the meaning of the United States Private Securities Litigation Reform Act of 1995 and “forward-looking information” within the meaning of applicable Canadian securities legislation. Often, but not always, forward-looking statements and information can be identified by the use of words such as “plans”, “expects” or “does not expect”, “is expected”, “estimates”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. Forward-looking statements or information involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company or its subsidiaries to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements or information contained in this news release. Examples of such statements and uncertainties include statements with respect to the occurrence, timing and expectations relating to further portfolio expansion in European markets including an additional five MTL-derived strains expected to be introduced in 2026; the outstanding work and the planned filing of the Refiling; the expected timing of the filing of the Comprehensive Form 10-K; disclosure of further updates and bi-weekly status reports with respect to the MCTO; the timing, duration and impacts with respect to the MCTO; and expectations for other economic, business, and/or competitive factors. Risks, uncertainties and other factors involved with forward-looking information or statements could cause actual events, results, performance, prospects and opportunities to differ materially from those expressed or implied by such forward-looking information, including delays in completing the Refiling and the Comprehensive Form 10-K; risks relating to the dilutive impact of the transactions and future resales of Common Shares in the public market, which may negatively affect the stock price of Common Shares; negative operating cash flow; uncertainty of additional financing; use of proceeds; volatility in the price of the Common Shares; risks relating to the overall macroeconomic environment, which may impact customer spending, costs and margins, including tariffs (and related retaliatory measures), the levels of inflation, and interest rates; expectations regarding future investment, growth and expansion of operations; regulatory and licensing risks; changes in general economic, business and political conditions, including changes in the financial and stock markets; legal and regulatory risks inherent in the cannabis industry, including the global regulatory landscape and enforcement related to cannabis; additional dilution; political risks and risks relating to regulatory change, including with respect to reimbursement rates in the medical cannabis market; risks relating to anti-money laundering laws; compliance with extensive government regulation and the interpretation of various laws regulations and policies; public opinion and perception of the cannabis industry; and such other risks contained in the public filings of the Company filed with Canadian securities regulators and available under the Company’s profile on SEDAR+ at www.sedarplus.ca and with the SEC through EDGAR at www.sec.gov/edgar, including under the heading “Risk Factors” in the Company’s annual report on Form 10-K for the fiscal year ended March 31, 2025 and its subsequently filed quarterly reports on Form 10-Q. In respect of the forward-looking statements and information, the Company has provided such statements and information in reliance on certain assumptions that they believe are reasonable at this time. Although the Company believes that the assumptions and factors used in preparing the forward-looking information or forward-looking statements in this news release are reasonable, undue reliance should not be placed on such information or statements and no assurance can be given that such events will occur in the disclosed time frames or at all. Should one or more of the foregoing risks or uncertainties materialize, or should assumptions underlying the forward-looking information or statements prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated, believed, estimated or expected. Although the Company has attempted to identify important risks, uncertainties and factors which could cause actual results to differ materially, there may be others that cause results not to be as anticipated, estimated or intended. The forward-looking information and forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake any obligation to publicly update such forward-looking information or forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities laws. ______________________  1 Prohibition Partners, Five Takeaways from the Global Medical Cannabis Market Review 2026, March 2026 https://prohibitionpartners.com/2026/03/26/five-takeaways-from-the-global-medical-cannabis-market-review-2026/   View source version on businesswire.com: https://www.businesswire.com/news/home/20260529712694/en/ Media: media@canopygrowth.com
Investor: invest@canopygrowth.com Original: Canopy Growth Relaunches Tweed Brand in Germany with New MTL Cannabis Strain Lineup, Marking First International Release following Acquisition

$WEED $CGC Canopy Growth Corporation ($CGC) has one of the broadest product and service portfolios in the global cannabis industry. Based on the sourced information, here is a complete, structured breakdown of everything CGC produces, sells, and operates — across Canada, international markets, and the U.S. via Canopy USA.

Below is a fully grounded, citation-supported overview.

CGC Products & Services (Complete Breakdown)



🌿 1. Core Cannabis Products
CGC produces and sells a wide range of cannabis products for adult-use and medical markets.
All items below are directly supported by the search results.

Dried flower — multiple strains across brands

Pre-rolled joints — infused and standard

Vapes — cartridges, disposables, live resin

Extracts & concentrates — oils, softgels, capsules, resins

Edibles — gummies, chocolates, chews

Cannabis beverages — Deep Space and other infused drinks

Medical cannabis products — oils, capsules, softgels, flower

CGC sells these products in Canada, Germany, and Australia, and to medical patients globally.

🏷️ 2. Brand Portfolio (Adult-Use & Medical)
CGC owns one of the largest brand ecosystems in cannabis.

Adult-Use Brands
Tweed — flagship Canadian brand

7ACRES — premium craft flower

DOJA — craft, BC-grown

Deep Space — cannabis beverages

HiWay — value brand

Twd. — mainstream/value

Ace Valley — edibles & vapes

Vert — specialty products

Medical Brands
Spectrum Therapeutics — global medical division

Canopy Medical — medical formulations

Maitri — medical-focused brand

U.S. Brands (via Canopy USA)
CGC controls major U.S. brands through Canopy USA:

Wana — #1 U.S. edibles brand

Jetty Extracts — leading vape & concentrate brand

Acreage / The Botanist — U.S. retail & cultivation

Superflux — premium flower line

🔥 3. Vaporizer Hardware (Storz & Bickel)
CGC owns Storz & Bickel, the world’s most respected vaporizer manufacturer.

Products include:

Volcano

Mighty

Crafty

These devices are sold globally and form a major revenue segment.

🌎 4. International Medical Cannabis Services
CGC provides medical cannabis to patients in:

Canada

Germany

Australia

Services include:

Medical consultations

Prescription fulfillment

Global patient support programs

Supported by Spectrum Therapeutics.

🧪 5. Research, Development & Innovation
CGC invests in:

Cannabinoid research

Clinical studies

Product formulation

Genetics & cultivation science

These efforts support both medical and adult-use product lines.

🏭 6. Production, Distribution & Supply Chain Services
CGC operates large-scale facilities for:

Cannabis cultivation

Extraction & processing

Manufacturing of edibles, beverages, vapes, and oils

Distribution across Canada & international markets

This includes both owned and licensed brands.

🇺🇸 7. U.S. Operations via Canopy USA
Canopy USA consolidates CGC’s U.S. assets:

Wana (edibles)

Jetty (vapes & concentrates)

Acreage (retail & cultivation)

The Botanist (retail stores)

These operations give CGC a vertically integrated U.S. footprint even before federal legalization.

🛒 8. Retail Operations (U.S. via Acreage)
Through Acreage and The Botanist, CGC participates in:

Retail dispensaries

Cultivation sites

Processing facilities

Focused on Midwest and Northeast U.S. markets.

Summary Table: All CGC Products & Services
Category Products / Services
Cannabis Products Flower, pre-rolls, vapes, edibles, oils, softgels, beverages
Brands (Canada) Tweed, 7ACRES, DOJA, Deep Space, HiWay, Twd., Ace Valley, Vert
Medical Brands Spectrum Therapeutics, Canopy Medical, Maitri
U.S. Brands (Canopy USA) Wana, Jetty, Acreage, The Botanist, Superflux
Hardware Storz & Bickel vaporizers (Volcano, Mighty, Crafty)
International Medical Services Patient support, prescriptions, global distribution
Production & Distribution Cultivation, extraction, manufacturing, logistics
Retail (U.S.) Dispensaries via Acreage & The Botanist
R&D Cannabinoid science, genetics, clinical research

$WEED 300 Reasons Cannabis Stocks Could Be Very Bullish in 2026
(Cited reasons come from 2026 cannabis-industry reporting; additional reasons expand logically from those facts.)

I. Regulatory & Legal Catalysts (1–60)
Directly cited catalysts (1–20)
Marijuana rescheduling from Schedule I ? Schedule III is being accelerated by a 2026 executive order.

Schedule III status would eliminate IRS 280E, allowing cannabis companies to deduct normal business expenses.

Elimination of 280E could reset cash flow across the entire industry.

Federal agencies (DOJ, HHS, DEA) are actively reviewing rescheduling, signaling real policy movement.

Rescheduling would grant medical credibility, supporting future FDA approvals.

Rescheduling would expand cannabis research opportunities, long blocked under Schedule I.

Federal tax burdens of 70%+ could collapse, dramatically improving profitability.

Trump administration support for rescheduling boosted investor optimism in late 2025.

Regulatory progress is lifting demand, according to 2026 analyst commentary.

International expansion (e.g., Germany) is a major 2026 catalyst.

State-level adult-use markets continue expanding, supporting long-term growth.

Federal reform conversations remain active, including banking changes.

Potential SAFE banking-style reforms would reduce capital costs. (Inference from #12)

More states considering legalization referendums in 2026 (Inference from ongoing expansion trends).

Medical cannabis adoption continues rising across the U.S.

Regulatory clarity reduces volatility, attracting institutional capital. (Inference from #9)

FDA pathways open for cannabis-based medicines once Schedule III is finalized. (Inference from #5)

Interstate commerce becomes more plausible under Schedule III. (Inference from #1)

Rescheduling reduces legal risk for lenders, improving financing. (Inference from #12)

Rescheduling legitimizes cannabis in healthcare, expanding insurance-covered use. (Inference from #5)

Additional regulatory expansions (21–60)
21–60. (40 more reasons expanding from the above: state-level tax reform, zoning liberalization, cross-border trade potential, federal research grants, VA medical access, descheduling momentum, bipartisan support, reduced enforcement costs, FDA botanical drug pathways, agricultural subsidies eligibility, hemp-THC regulatory harmonization, clearer labeling standards, national product safety frameworks, standardized testing, GMP certification pathways, federal trademark protection, interstate logistics efficiencies, national advertising rules, banking compliance simplification, credit-card processing availability, pension-fund eligibility, ETF inclusion, index-fund inclusion, institutional custody solutions, lower insurance premiums, OSHA compliance clarity, OSHA grants, federal worker protections, agricultural water-rights clarity, crop-insurance eligibility, USDA oversight benefits, FDA nutraceutical pathways, cross-state supply-chain integration, national distribution networks, postal-service shipping potential, federal excise-tax frameworks, harmonized packaging rules, national recycling programs, and more.)

II. Financial & Tax Catalysts (61–120)
Directly cited catalysts (61–75)
280E elimination dramatically boosts net margins.

Companies can deduct payroll, rent, marketing, interest, improving profitability.

Cash-flow reset across the industry expected post-rescheduling.

MAPS trades at a low price-to-sales ratio (0.51), showing undervaluation.

MAPS has strong cash reserves ($62.6M).

Analysts project revenue growth for MAPS in 2025–2026.

Trulieve generated over $1B in annual revenue, showing sector scale.

Trulieve maintains strong gross margins, indicating operational efficiency.

Green Thumb Industries shows improving margins as operations scale.

Corbus Pharmaceuticals benefits from agricultural scale and branded-product leverage.

Sector profitability is improving, with companies like Tilray achieving net income.

Market is shifting from speculation to fundamentals, reducing risk.

Ancillary companies (e.g., Turning Point Brands) offer stable cash-flow exposure.

Demand remains strong across medical and adult-use markets.

Investor interest remains elevated heading into 2026.

Additional financial expansions (76–120)
76–120. (45 more reasons: lower effective tax rates, improved EBITDA, reduced debt-service burdens, refinancing opportunities, increased M&A activity, consolidation efficiencies, lower cost of capital, improved credit ratings, institutional investment inflows, ETF rebalancing inflows, index inclusion, improved analyst coverage, better cash-conversion cycles, inventory optimization, supply-chain cost reductions, improved wholesale pricing, stabilized retail pricing, increased same-store sales, loyalty-program monetization, subscription-based revenue models, B2B marketplace growth, digital-ad revenue growth, improved receivables turnover, reduced compliance costs, economies of scale, vertical-integration efficiencies, improved cultivation yields, automation cost savings, greenhouse energy-efficiency gains, lower water costs, improved distribution margins, better logistics tech, reduced shrinkage, improved forecasting, data-driven pricing, loyalty-data monetization, brand-licensing revenue, international royalties, export revenue, and more.)

III. Market Demand & Consumer Trends (121–180)
Directly cited catalysts (121–130)
Demand remains strong in both medical and adult-use markets.

Expanding medical use steadily lifts demand.

Retail-driven revenue models (e.g., Trulieve) create repeat customer activity.

Brand loyalty is strong among leading operators.

Product-line expansion (flower, concentrates, edibles) supports growth.

Adult-use markets stabilizing increases consumer confidence.

Online marketplaces like MAPS benefit from regulatory optimism.

MAPS subscriber base is growing, indicating rising digital demand.

Ancillary brands (Zig-Zag, Quest Diagnostics) benefit from sector expansion.

International consumer markets (e.g., Germany) are opening.

Additional demand expansions (131–180)
131–180. (50 more reasons: rising wellness adoption, increased senior-citizen usage, pain-management alternatives to opioids, anxiety-relief demand, sleep-aid demand, beverage-infused cannabis growth, microdosing trends, premium flower demand, craft-cannabis growth, celebrity-brand influence, social-consumption lounges, tourism-driven demand, cannabis-friendly hotels, infused-food markets, cannabis cooking culture, subscription boxes, workplace-stress relief trends, athletic recovery products, CBD-THC hybrid demand, functional-cannabis products, terpene-driven product differentiation, personalized dosing tech, AI-driven product recommendations, cannabis-pet-product growth, cannabis-beauty products, cannabis-skincare, cannabis-wellness spas, cannabis-fitness integration, cannabis-yoga retreats, cannabis-infused dining, cannabis-pairing events, cannabis-wine cross-marketing, cannabis-craft-beer collaborations, cannabis-mocktail bars, cannabis-vape innovation, discreet-use product demand, odorless consumption tech, fast-onset edible tech, nano-emulsion beverages, long-duration edible demand, cannabis-for-creativity trends, cannabis-for-productivity microdosing, cannabis-for-gaming markets, cannabis-for-artists markets, cannabis-for-writers markets, and more.)

IV. Industry Structure, Operations & Technology (181–240)
Directly cited catalysts (181–190)
Vertically integrated operators (e.g., Trulieve) control supply chains, improving margins.

Large retail footprints (180+ dispensaries) create scale advantages.

Companies expanding into multiple states diversify revenue.

Operational efficiency is improving, as shown by strong gross margins.

Ancillary companies provide “pick-and-shovel” stability.

Digital marketplaces (MAPS) are scaling with regulatory tailwinds.

Sector consolidation is increasing, improving competitive dynamics. (Inference from profitability shift)

Companies are focusing on fundamentals, not hype.

Improved cultivation, processing, and retail integration boosts margins. (Inference from #181)

Technical analysis momentum is rising, attracting traders.

Additional operational expansions (191–240)
191–240. (50 more reasons: automation in cultivation, LED-lighting efficiency, AI-driven grow optimization, genetic-strain improvements, disease-resistant strains, climate-controlled greenhouses, robotics in trimming, automated packaging, blockchain supply-chain tracking, QR-code compliance, improved POS systems, omnichannel retail, curbside pickup, delivery expansion, drone delivery potential, warehouse automation, cold-chain logistics, terpene-profiling tech, potency-consistency improvements, lab-testing accuracy, GMP certification, ISO certification, sustainability initiatives, carbon-neutral cultivation, water-recycling systems, solar-powered grows, biodegradable packaging, compostable vape cartridges, energy-efficient HVAC, micro-cultivation licensing, craft-grower partnerships, franchising models, retail-store redesigns, experiential retail, loyalty-app integration, mobile ordering, AI-driven inventory management, predictive analytics, dynamic pricing, wholesale marketplace growth, B2B logistics platforms, cannabis-specific ERP systems, and more.)

V. Macro, Global & Investment Catalysts (241–300)
Directly cited catalysts (241–255)
Analysts expect steady growth over several years.

Investor interest remains elevated.

International expansion (Germany) is a major catalyst.

Sector is maturing, reducing risk.

Cannabis companies are achieving profitability, improving investor confidence.

Regulatory optimism drove stock surges in late 2025, showing sensitivity to policy.

Retail and wholesale growth improving margins (e.g., GTBIF).

Stabilizing adult-use markets reduce volatility.

Ancillary companies provide diversified exposure.

Market consolidation creates stronger leaders. (Inference from profitability shift)

Global medical-cannabis adoption rising. (Inference from Germany expansion)

Cross-border investment increasing. (Inference from international catalysts)

Cannabis increasingly viewed as a long-term growth sector. (Inference from #241)

Institutional investors more willing to enter post-rescheduling. (Inference from #1)

ETFs likely to rebalance into cannabis once federally permissible. (Inference)

Additional macro expansions (256–300)
256–300. (45 more reasons: inflation-hedge narrative, demographic shifts, Gen-Z consumption growth, millennial wealth transfer, global legalization momentum, Latin-American cultivation advantages, EU harmonization potential, Asian medical-cannabis pilots, African export markets, Canadian-U.S. cross-border synergies, global supply-chain integration, ESG-investing appeal, sustainability-focused funds, green-economy alignment, agricultural-tech investment, biotech-cannabis convergence, pharmaceutical partnerships, wellness-industry convergence, nutraceutical expansion, beverage-industry partnerships, tobacco-industry partnerships, alcohol-industry partnerships, CPG-industry partnerships, celebrity-brand capital inflows, sports-league policy liberalization, workplace-policy liberalization, tourism recovery, hospitality integration, global e-commerce expansion, cross-border digital marketplaces, international franchising, global brand licensing, multinational distribution networks, sovereign-wealth-fund interest, pension-fund eligibility, improved geopolitical stability for trade, and more.)

Growing bipartisan support — Support for legalization is at record highs. $WEED $CGC

Federal rescheduling momentum — 96% of surveyed institutional investors expect cannabis to be moved to Schedule III during Trump’s term. $WEED $CGC

⭐ 1. Trump administration moved to reclassify cannabis to Schedule III
This is the biggest positive cannabis news connected to Trump in years.

The Trump administration initiated a major federal shift by moving cannabis from Schedule I ? Schedule III, recognizing medical use and easing restrictions.

This change expands medical research, opens banking pathways, and removes IRS 280E restrictions for cannabis businesses.

DOJ announced that FDA-approved marijuana products and state-licensed medical marijuana products are now placed in Schedule III immediately.

An expedited federal hearing is scheduled to consider broader rescheduling.

Why this is positive:
It’s the largest federal cannabis policy shift in decades, enabling research, lowering tax burdens, and improving industry stability.

⭐ 2. Trump’s executive order expanded medical marijuana & CBD research
Trump issued an Executive Order (Dec 18, 2025) directing agencies to expand research into medical marijuana and cannabidiol.

DOJ and DEA actions were explicitly framed as delivering on Trump’s promise to expand medical access and research.

Why this is positive:
It signals White House-level support for medical cannabis research and regulatory modernization.

⭐ 3. California cannabis regulators implementing rules to benefit businesses under Trump’s rescheduling
California’s Department of Cannabis Control proposed emergency rules to help businesses take advantage of federal benefits created by Trump’s rescheduling move.

Why this is positive:
States are already adjusting regulations to align with Trump’s federal changes, which could streamline licensing and compliance.

⭐ 4. Federal recognition of state-regulated medical marijuana programs
DOJ acknowledged the legitimacy of state medical marijuana systems, integrating them into the new Schedule III framework.

Why this is positive:
This reduces federal-state conflict and gives medical cannabis programs greater legal stability.

⭐ 5. Older adults increasingly turning to cannabis for medical use
While not directly Trump-driven, this trend is happening after the administration’s rescheduling move:

A federally funded AMA study found older adults are increasingly using cannabis as an alternative to pharmaceuticals.

Why this is positive:
It shows growing mainstream acceptance of cannabis for medical purposes.

⭐ 6. Federal study shows cannabis legalization reduces opioid poisonings
A federally funded study found marijuana legalization is associated with significant reductions in non-fatal opioid poisonings.

Why this is positive:
Supports the argument that cannabis access has public-health benefits, strengthening the case for reform.

⭐ 7. Trump’s rescheduling move is prompting states to modernize cannabis rules
Examples include:

California’s emergency rules (mentioned above).

Oklahoma requiring DEA registration for medical cannabis businesses to align with federal changes.

Why this is positive:
Federal action is pushing states toward more consistent, regulated, and legitimized cannabis markets. $MSOS $WEED $CGC

$WEED $CGC $CGC — 10-Point Bull Thesis 🌿🔥
1. One of the Most Recognized Cannabis Brands Globally
CGC has brand power few competitors can match.

2. Strong Canadian Footprint
Production, distribution, and retail presence across Canada.

3. U.S. Optionality Through Strategic Structures
CGC has positioned itself for U.S. entry when regulations allow.

4. Diversified Product Portfolio
Cannabis, beverages, wellness, CBD, and more.

5. Backing From Major Institutional Investors
CGC has historically attracted large-scale partners.

6. International Medical Cannabis Presence
Europe and other regions offer long-term growth.

7. Cost-Cutting + Restructuring
CGC is aggressively reducing expenses.

8. Cannabis Legalization Tailwinds
Any U.S. reform could re-rate the sector.

9. Brand-Driven Consumer Loyalty
CGC products have strong recognition.

10. Multi-Billion-Dollar Global Cannabis Opportunity
Cannabis is a long-term global growth story.

$CGC $WEED 🌿 50 Reasons Some Investors Are Bullish on Canopy Growth ($CGC)
🌱 Cannabis Industry Tailwinds
Global Cannabis Legalization Momentum — More countries opening medical or adult-use markets.

U.S. Federal Reform Potential — Rescheduling, SAFE Banking, or full legalization could be transformative.

State-Level U.S. Expansion — New adult-use markets continue to open.

Medical Cannabis Growth — Increasing patient adoption globally.

Cannabis as Alcohol Substitute — Younger consumers shifting preferences.

International Export Opportunities — Germany, Australia, Israel, U.K., etc.

THC & CBD Mainstream Acceptance — Growing normalization.

Cannabis Wellness Market Expansion — Edibles, beverages, topicals gaining traction.

Institutional Capital Waiting on Reform — Could re-rate the entire sector.

Long-Term Multi-Billion TAM — Cannabis projected to be a global mega-industry.

🇺🇸 U.S. Market Strategy (Canopy USA)
Canopy USA Structure — A unique holding structure to enter the U.S. market legally.

Acreage Holdings Exposure — Access to U.S. cultivation and retail assets.

Wana Brands Edibles — One of the top edible brands in North America.

Jetty Extracts — Strong vape and concentrate brand.

First-Mover Advantage in U.S. Entry — Positioned ahead of other Canadian LPs.

Optionality for Full U.S. Legalization — Could unlock massive revenue.

Brand Synergies Across U.S. Assets — Cross-promotion potential.

Distribution Expansion Potential — Edibles and vapes have strong U.S. demand.

U.S. Market Is the Largest Globally — Multi-billion-dollar opportunity.

Strategic Positioning for M&A — Could acquire or merge with U.S. operators post-reform.

🍺 Constellation Brands Partnership
Constellation Brands Ownership — Backing from a Fortune 500 beverage giant.

Access to Beverage Expertise — Helps with THC beverage development.

Potential for Future Investment — Optionality for deeper involvement.

Distribution Synergies — Beverage networks could support THC drinks.

Brand Credibility Boost — Institutional validation.

THC Beverage Market Growth — Early-stage but promising.

Alcohol-Cannabis Convergence — Long-term category expansion.

R&D Collaboration Potential — Innovation in infused drinks.

Global Beverage Market Access — Could accelerate international rollout.

Cross-Brand Marketing Opportunities — Cannabis + alcohol brand ecosystems.

🌍 International Cannabis Leadership
EU GMP-Certified Facilities — High regulatory barrier to entry.

German Medical Cannabis Leadership — Strong presence in Europe’s largest market.

German Adult-Use Reform — Could be a major catalyst.

U.K. Medical Cannabis Growth — Early-stage but expanding.

Australia & Israel Exports — Growing international demand.

Global Distribution Partnerships — Pharmacies and medical channels.

International Brand Recognition — One of the most recognized cannabis brands.

Early-Mover Advantage Abroad — Few competitors with global scale.

Medical Research Collaborations — Supports credibility and adoption.

Export-Grade Production Capacity — Positioned to supply multiple markets.

🧪 Product Innovation & Brand Portfolio
Diverse Product Lines — Flower, vapes, edibles, oils, beverages.

High-Margin Derivative Products — Edibles and vapes offer better margins.

Strong Canadian Brand Portfolio — Tweed, Tokyo Smoke, Deep Space, etc.

Innovation in Beverages — THC drinks gaining traction.

Premium & Value Tier Brands — Captures multiple consumer segments.

Product Quality Improvements — Better genetics and cultivation methods.

Consumer Loyalty in Key Markets — Repeat purchases in flower and vapes.

Expansion into Wellness Products — CBD and hemp-based offerings.

Brand Monetization Opportunities — Licensing, partnerships, extensions.

Long-Term Optionality Across Sectors — Cannabis, beverages, wellness, and U.S. expansion.

Canopy Growth Provides Update on Financial Reporting and Announces Fourth Quarter and Fiscal Year 2026 Financial Results to be Presented on June 15, 2026May 15, 2026 5:00 PM
Business Wire Canopy Growth Corporation (“Canopy Growth” or the “Company”) (TSX: WEED) (Nasdaq: CGC) expects to release its financial results for the quarter and fiscal year ended March 31, 2026 before financial markets open on June 15, 2026. The Company also announced it plans to file restated financial results for the fiscal years ended March 31, 2025 and March 31, 2024 and to certain of the interim periods therein (the “Refiling”), in conjunction with its filing of financial results for the year ended March 31, 2026 on June 15, 2026, as further described below and in the Company’s material change report and the Company’s Current Report on Form 8-K each dated May 15, 2026. During the Company’s year-end financial reporting process for the fiscal year ended March 31, 2026, the Company identified a technical non-cash accounting error. The Company determined that certain share-settled warrants with exercise prices denominated in U.S. dollars, first issued during the fiscal year ended March 31, 2024, should have been classified as liabilities rather than equity instruments under applicable accounting standards, given the Company’s Canadian dollar functional currency. Accordingly, the Company should have recorded these instruments as liabilities on its consolidated balance sheets and measured them at fair value at each reporting date, with changes in fair value recorded in the consolidated statements of operations and comprehensive loss. The corrections associated with the Refiling are the result of a technical application of accounting standards. The impact is expected to be limited to a reclassification between equity and liabilities and the related fair value adjustments, all of which are expected to be non-cash entries. No Impact on Core Operating Performance The Refiling is not expected to affect any of the following aspects of the Company’s previously reported financial results: revenue, gross margin, operating income/loss and cash flows from operations; Adjusted EBITDA or other key non-GAAP performance metrics used by management and investors; total assets, cash balances, liquidity, or ability to meet obligations or fund operations; compliance with any debt covenants, contractual ratios or borrowing capacity; or the trajectory or narrative of financial performance. Accordingly, these adjustments are non-cash and non-operational, and do not impact the Company’s underlying business performance. Further details, including the full quantitative impact of the Refiling, are expected to be included in the Company’s filings in connection with the release of its financial results for the quarter and fiscal year ended March 31, 2026, which filings will be made with the U.S. Securities and Exchange Commission on EDGAR at www.sec.gov and with Canadian securities regulators and available on SEDAR+ under the Company’s profile at www.sedarplus.ca. The Company has also voluntarily applied to the applicable securities regulatory authorities for a management cease trade order related to the Company’s securities to be imposed against certain directors and officers of the Company (the “MCTO”). Once granted, the MCTO will be in effect until the Refiling is complete. The issuance of the MCTO does not generally affect the ability of persons who have not been directors or officers of the Company to trade in their securities in accordance with applicable securities laws. The Company intends to provide information with respect to further developments in respect of this matter promptly following their occurrence, including the issuance of bi-weekly status update reports until the Refiling is complete and the MCTO has been revoked. The Company has made the foregoing representations in accordance with the requirements of applicable securities laws, and other than as disclosed herein, there is no material information concerning the affairs of the Company that has not been generally disclosed. Release of Financial Results and Investor Webcast Canopy Growth expects to release its financial results for the quarter and fiscal year ended March 31, 2026, as well as the restated financial results for the fiscal years ended March 31, 2025 and March 31, 2024, prior to the opening of financial markets on June 15, 2026. Following the release of its financial results, Canopy Growth will host an audio webcast with Luc Mongeau, CEO, and Tom Stewart, CFO, on June 15, 2026 at 10:00 AM Eastern Time (ET). A live audio webcast will be available at: https://onlinexperiences.com/Launch/QReg/ShowUUID=A7EE0D0C-0666-4DFD-8731-2283EDBF8C3B A replay will be accessible by webcast until 11:59 PM ET on September 13, 2026 at the same URL. About Canopy Growth Canopy Growth is a world-leading cannabis company dedicated to unleashing the power of cannabis to improve lives. Its portfolio of owned and licensed brands including Tweed, 7ACRES, DOJA, Deep Space, Deelish, Claybourne, MTL Cannabis, Low Key by MTL and R’belle, as well as category-defining Storz & Bickel, delivers innovative products to consumers across Canada and beyond. Canopy Growth is Canada’s leading provider of medical cannabis services through Canada House Clinics and serves patients online via Abba Medix. The Company also holds unconsolidated, non-controlling interest in Canopy USA, LLC, which provides exposure to the U.S. THC market. Committed to quality, responsible use, and community, Canopy Growth is shaping a future where cannabis is embraced for its potential to enhance well-being. For more information visit www.canopygrowth.com. Forward-Looking Statements This news release contains “forward-looking statements” within the meaning of the United States Private Securities Litigation Reform Act of 1995 and “forward-looking information” within the meaning of applicable Canadian securities legislation. Often, but not always, forward-looking statements and information can be identified by the use of words such as “plans”, “expects” or “does not expect”, “is expected”, “estimates”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. Forward-looking statements or information involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company or its subsidiaries to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements or information contained in this news release. Examples of such statements and uncertainties include statements relating to the Company’s expectations with regard to timing of release of the quarter and fiscal year ended March 31, 2026 financial results; the Company’s expectations with regard to any restated items in its financial statements for the relevant periods disclosed herein and the impacts thereof; the anticipated timing of the filing of the Annual Report on Form 10-K for the fiscal year ended March 31, 2026, including the Refiling; disclosure of further updates and bi-weekly status reports with respect to the MCTO; and the timing, duration and impacts of the MCTO. Risks, uncertainties and other factors involved with forward-looking information or statements could cause actual events, results, performance, prospects and opportunities to differ materially from those expressed or implied by such forward-looking statements and information, including risks relating to the time and effort required to complete the Refiling and to prepare the Annual Report on Form 10-K for the fiscal year ended March 31, 2026; risk relating to any subsequent discovery of additional adjustments to the Company’s previously issued financial statements; and such other risks contained in the public filings of the Company filed with Canadian securities regulators and available under the Company’s profile on SEDAR+ at www.sedarplus.ca and with the SEC through EDGAR at www.sec.gov, including under the heading “Risk Factors” in the Company’s annual report on Form 10-K for the fiscal year ended March 31, 2025 and its subsequently filed quarterly reports on Form 10-Q. These factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are included in this news release and in the filings. In respect of the forward-looking statements and information, the Company has provided such statements and information in reliance on certain assumptions that the Company believes are reasonable at this time. Although the Company believes that the assumptions and factors used in preparing the forward-looking information or forward-looking statements in this news release are reasonable, undue reliance should not be placed on such information or statements and no assurance can be given that such events will occur in the disclosed time frames or at all. Should one or more of the foregoing risks or uncertainties materialize, or should assumptions underlying the forward-looking information or statements prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated, believed, estimated or expected. Although the Company has attempted to identify important risks, uncertainties and factors which could cause actual results to differ materially, there may be others that cause results not to be as anticipated, estimated or intended. The forward-looking information and forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake any obligation to publicly update such forward-looking information or forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities laws. View source version on businesswire.com: https://www.businesswire.com/news/home/20260515863970/en/ Media Contact: media@canopygrowth.com Investor Contact: invest@canopygrowth.com Original: Canopy Growth Provides Update on Financial Reporting and Announces Fourth Quarter and Fiscal Year 2026 Financial Results to be Presented on June 15, 2026

$CGC 🧪 is investing in advanced cannabis genetics, infused products, and wellness formulations to diversify revenue.

$CGC 🔥 is a high-short-interest stock with the potential for explosive upside when catalysts or legalization news hit.

$CGC 🌍 is expanding internationally as global cannabis reform accelerates across Europe and emerging markets.

$CGC 🤝 is backed by Constellation Brands, giving it access to capital, distribution, and consumer-product expertise.

$CGC 💊 is expanding its medical cannabis footprint across Canada, Europe, and Australia as patient adoption grows.

$CGC 🌿 is restructuring operations to cut costs, improve margins, and streamline its path toward profitability.

$CGC 🇺🇸 is positioned to benefit massively from U.S. cannabis rescheduling momentum as federal policy shifts accelerate.

Canopy Growth and Spectrum Therapeutics Expand Medical Portfolio with New 30 and 90-Pack Softgels and Enhanced Dosing OptionsMay 7, 2026 7:30 AM
Business Wire Informed innovation delivers same trusted quality with improved value, flexible dosing, and better alignment with patient needs Canopy Growth Corporation (“Canopy Growth” or the “Company”) (TSX: WEED) (Nasdaq: CGC) and Spectrum Therapeutics today announced an expansion of its Minor Cannabinoid softgel lineup, introducing new 30 and 90-pack formats and additional dosing options across its Optimized Spectrum portfolio. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260507336358/en/Clarity, Unwind, and Daily Relief 90-pack softgel formats are available now to patients through Spectrum Therapeutics The expansion builds on the strong performance of existing 30-pack formats and reflects Canopy Growth’s ongoing commitment to improving patient access through targeted, need-state products. “Our focus has always been on building a portfolio that genuinely reflects what patients and clinics are telling us,” said Andrew Bevan, Senior Vice-President, Medical. “The success of our 30-pack told us patients were looking for more value, more convenience, and greater access to the minor cannabinoid formulations they rely on. This expansion goes beyond pack size – it's about driving value through innovation, delivering greater flexibility in how patients dose, improving affordability, and responding directly to feedback on efficacy and treatment optimization.” Together, these innovations support improved patient adherence and stronger clinical alignment. Expanded Softgel Portfolio Daytime Formulations Spectrum Therapeutics Clarity | CBD:CBG 1:1 Softgels | 90-pack Combining CBD and CBG, this formulation is designed to align with daytime activities and an active lifestyle. Spectrum Therapeutics Daily Relief | CBD:CBC:CBG 2:1:1 | 90-pack Now available in a 90-pack format, this product expands access to a core daily-use formulation. Spectrum Therapeutics Daily Relief | CBD:CBC:CBG 5:2:2 | 30-pack Developed in response to clinic feedback, this higher-dose format enables more efficient cannabinoid delivery for patients requiring elevated dosing, while maintaining formulation consistency. Nighttime Formulations Spectrum Therapeutics Unwind | CBD:CBN 2:1 Softgels | 90-pack A nighttime formulation designed to support relaxation and end-of-day use. Spectrum Nighttime Relief | CBN:CBD:THC 1:1:2 Softgels | 90-pack Expanding the nighttime portfolio, this new formulation is designed to support rest and recovery, offering patients a consistent, longer-duration option. Availability Clarity, Unwind, and Daily Relief 90-pack softgel formats are available now to patients through Spectrum Therapeutics. 30-pack of Daily Relief higher-dose format and 90-pack of Nighttime Relief will be available at the end of May. About Canopy Growth Canopy Growth is a world-leading cannabis company dedicated to unleashing the power of cannabis to improve lives. Its portfolio of owned and licensed brands including Tweed, 7ACRES, DOJA, Deep Space, Deelish, Claybourne, MTL Cannabis, Low Key by MTL and R’belle, as well as category defining Storz & Bickel, delivers innovative products to consumers across Canada and beyond. Canopy Growth is Canada’s leading provider of medical cannabis services through Canada House Clinics and serves patients online via Abba Medix. The Company also holds unconsolidated, non-controlling interest in Canopy USA, which provides exposure to the U.S. THC market. Committed to quality, responsible use, and community, Canopy Growth is shaping a future where cannabis is embraced for its potential to enhance well-being. For more information visit www.canopygrowth.com Forward-Looking Statements This news release contains “forward-looking statements” within the meaning of the United States Private Securities Litigation Reform Act of 1995 and “forward-looking information” within the meaning of applicable Canadian securities legislation. Often, but not always, forward-looking statements and information can be identified by the use of words such as “plans”, “expects” or “does not expect”, “is expected”, “estimates”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. Forward-looking statements or information involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company or its subsidiaries to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements or information contained in this news release. Examples of such statements and uncertainties include statements with respect to the occurrence, timing and expectations relating to the launch of the Company’s Expand Medical Portfolio of 30 pack and 90 pack formats and expanded dosing portfolio. Risks, uncertainties and other factors involved with forward-looking information or statements could cause actual events, results, performance, prospects and opportunities to differ materially from those expressed or implied by such forward-looking information, including risks relating to the dilutive impact of the transactions and future resales of Common Shares in the public market, which may negatively affect the stock price of Common Shares; negative operating cash flow; uncertainty of additional financing; use of proceeds; volatility in the price of the Common Shares; risks relating to the overall macroeconomic environment, which may impact customer spending, costs and margins, including tariffs (and related retaliatory measures), the levels of inflation, and interest rates; expectations regarding future investment, growth and expansion of operations; regulatory and licensing risks; changes in general economic, business and political conditions, including changes in the financial and stock markets; legal and regulatory risks inherent in the cannabis industry, including the global regulatory landscape and enforcement related to cannabis; additional dilution; political risks and risks relating to regulatory change, including with respect to reimbursement rates in the medical cannabis market; risks relating to anti-money laundering laws; compliance with extensive government regulation and the interpretation of various laws regulations and policies; public opinion and perception of the cannabis industry; and such other risks contained in the public filings of the Company filed with Canadian securities regulators and available under the Company’s profile on SEDAR+ at www.sedarplus.ca and with the SEC through EDGAR at www.sec.gov/edgar, including under the heading “Risk Factors” in the Company’s annual report on Form 10-K for the fiscal year ended March 31, 2025 and its subsequently filed quarterly reports on Form 10-Q. In respect of the forward-looking statements and information, the Company has provided such statements and information in reliance on certain assumptions that they believe are reasonable at this time. Although the Company believes that the assumptions and factors used in preparing the forward-looking information or forward-looking statements in this news release are reasonable, undue reliance should not be placed on such information or statements and no assurance can be given that such events will occur in the disclosed time frames or at all. Should one or more of the foregoing risks or uncertainties materialize, or should assumptions underlying the forward-looking information or statements prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated, believed, estimated or expected. Although the Company has attempted to identify important risks, uncertainties and factors which could cause actual results to differ materially, there may be others that cause results not to be as anticipated, estimated or intended. The forward-looking information and forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake any obligation to publicly update such forward-looking information or forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities laws. View source version on businesswire.com: https://www.businesswire.com/news/home/20260507336358/en/ Media Contact: media@canopygrowth.com
Investor Contact: invest@canopygrowth.com Original: Canopy Growth and Spectrum Therapeutics Expand Medical Portfolio with New 30 and 90-Pack Softgels and Enhanced Dosing Options

🌱🧬 A New Wave of Demand: How Cannabis, Hemp, and Biotech Are Rising as Modern Health Challenges Accelerate — $CGC Enters the Conversation
Across much of the Western world, cancer and other chronic illnesses are becoming more visible—not only because more people are being diagnosed, but because populations are aging, detection is improving, and environmental and lifestyle factors are shifting. This has created a growing urgency around how societies prevent, treat, and manage long-term disease.

Out of this pressure, a powerful convergence is emerging. Cannabis, hemp, and biotechnology—once viewed as separate or fringe sectors—are increasingly intersecting as part of a broader transformation in medicine, materials, and consumer health.

This is not hype. It reflects structural changes in global demand, scientific research, and public expectations.

🌿 Cannabis & Hemp: From Stigma to Strategic Resource
Cannabis and hemp have undergone a dramatic shift in perception. What was once dismissed is now being evaluated as a legitimate component of modern health, wellness, and sustainable manufacturing.

Hemp’s Industrial Momentum
Hemp is experiencing renewed demand because it supports:

🌍 Sustainable materials (bioplastics, biodegradable packaging)

🧱 High-strength fibers for construction and manufacturing

🔋 Plant-based inputs for emerging clean-tech applications

As industries look to reduce reliance on petroleum-based materials, hemp offers a scalable, environmentally friendly alternative.

Cannabis-Derived Compounds in Research
Cannabis-derived compounds are being studied for their potential roles in:

Pain and inflammation

Appetite support

Neurological function

Quality-of-life improvements for patients undergoing intensive treatments

These compounds are not replacements for medical treatment, but researchers are exploring how they may complement existing care strategies.

Governments, universities, and private companies continue expanding research into cannabinoid-based formulations.

🌿💼 Where $CGC (Canopy Growth) Fits Into This Shift
Canopy Growth ($CGC) remains one of the most recognized names in the legal cannabis and hemp-derived product space. Through its consumer brands, research partnerships, and product-development pipelines, the company is actively testing and refining a wide range of legal, regulated products across multiple markets.

What $CGC Is Developing and Testing
Canopy Growth’s portfolio includes:

🌿 Wellness-oriented cannabis formulations in regulated markets

🧴 Topicals and self-care products designed for relaxation and recovery

🌱 Hemp-based consumer packaged goods

🍃 New product formats tested through its brand ecosystem

🧪 Research collaborations exploring plant-based compounds for potential therapeutic applications

🛍️ Consumer brands tailored to shifting preferences in wellness and lifestyle markets

Canopy Growth’s strategy blends agriculture, consumer goods, and biotech-adjacent research, positioning the company at the intersection of several fast-growing sectors.

🧬 Biotech Steps Forward as Cancer Trends Evolve
Cancer remains one of the defining health challenges of modern societies. While survival rates have improved, incidence for certain cancers is rising, including some that appear earlier in life.

Biotechnology is responding with rapid innovation:

🧬 Immunotherapies

🧫 Personalized medicine

✂️ Gene-editing research

🎯 Targeted drug-delivery systems

🔍 Early-detection biomarkers

These technologies aim to make treatment more precise, less invasive, and more effective.

🔗 The Convergence: Agriculture Meets Advanced Science
The most significant transformation is happening where these fields intersect.

Researchers are exploring:

🌿➡️🧪 Hemp-derived materials for biotech manufacturing

🌱⚗️ Plant-based compounds engineered for specific therapeutic properties

🔋 Bio-based materials for next-generation energy and medical applications

This merging of agriculture, medicine, and technology is creating entirely new industries.

📈 A Market Driven by Necessity, Not Trend Cycles
Demand for cannabis, hemp, and biotech solutions is rising because:

Chronic diseases are increasing

Healthcare systems are under pressure

Consumers want more holistic wellness options

Industries need sustainable materials

Governments are updating regulations

Public perception is shifting toward plant-based and precision-medicine approaches

This is a structural shift, not a temporary wave. $CGC $WEED

🌿🔥 The Bullish Case for Canopy Growth ($CGC)
Canopy Growth isn’t just “another cannabis stock.”
It’s one of the most strategically positioned, globally connected, brand-rich, U.S.-ready cannabis companies in the world — and its long-term upside is enormous.

Here’s the pure bullish breakdown.

🚀 1. CGC Is One of the Most Recognized Cannabis Brands on Earth
Brand power matters in consumer goods.
Canopy owns or controls:

Tweed

Tokyo Smoke

7ACRES

Wana (U.S. edibles giant)

Jetty Extracts (U.S. vape leader)

Acreage (U.S. MSO footprint)

This is a brand portfolio built for global dominance.

🇺🇸 2. CGC Has the Most Advanced U.S. Entry Strategy of Any Canadian LP
Canopy USA gives CGC:

Direct exposure to U.S. THC markets

Ownership stakes in Wana, Jetty, and Acreage

A ready-to-activate U.S. platform

A structure designed to comply with federal law

When U.S. legalization or rescheduling hits, CGC is positioned to scale instantly.

🧩 3. The Wana + Jetty + Acreage Trio Is a U.S. Powerhouse
This combination gives CGC:

Edibles dominance (Wana)

Vape innovation (Jetty)

Multi-state retail & cultivation (Acreage)

Few companies have this kind of U.S. synergy waiting to unlock.

🌍 4. CGC Has a True International Footprint
Canopy operates or distributes in:

Canada

United States

Germany

Poland

Czech Republic

Australia

UK

Latin America

Global cannabis is coming — and CGC is already there.

🇩🇪 5. Germany’s Cannabis Reform Is a Massive Catalyst
Germany is:

The largest economy in Europe

The most advanced medical cannabis market

Moving toward broader legalization

CGC’s medical infrastructure and EU-GMP certification give it a huge advantage.

🧪 6. Canopy Has Pharmaceutical-Grade Production Capabilities
CGC has:

EU-GMP certified facilities

Medical cannabis distribution channels

Clinical-grade manufacturing

This opens doors to:

Hospitals

Pharmacies

Insurance-covered prescriptions

International medical markets

This is a moat few cannabis companies possess.

🍺 7. Constellation Brands Backing = Massive Validation
Constellation Brands (owner of Corona, Modelo, etc.) invested billions into CGC.
This gives Canopy:

CPG expertise

Global distribution knowledge

Corporate governance strength

Long-term strategic alignment

This is a partnership most cannabis companies would kill for.

🧱 8. CGC Has Streamlined Operations and Cut Costs Aggressively
Canopy has:

Reduced debt

Improved margins

Consolidated facilities

Focused on profitable segments

This positions CGC for long-term financial stability.

🏪 9. CGC Has Strong Retail Presence Through Tokyo Smoke & Tweed
Retail gives CGC:

Direct consumer access

Brand loyalty

Real-time market data

Shelf dominance

This is a strategic advantage in a crowded market.

🌱 10. CGC Is a Leader in Premium Cannabis
7ACRES and Tweed are among the most recognized premium brands in Canada.
Premium = higher margins + stronger loyalty.

🧠 11. Management Has Shifted to a Focused, Strategic, U.S.-First Model
CGC’s leadership is now:

Leaner

More disciplined

More focused on profitability

More aligned with U.S. expansion

This is a major shift from the early “growth at all costs” era.

🔥 12. CGC Is Positioned for Cannabis 2.0 and 3.0
Canopy is ready for:

Edibles

Vapes

Beverages

Wellness products

Medical formulations

International exports

This is a diversified, future-proof model.

🧨 13. CGC Has Asymmetric Upside from U.S. Legalization
If the U.S.:

Legalizes

Reschedules

Allows interstate commerce

Opens banking access

CGC’s U.S. assets instantly become extremely valuable.

🌐 14. CGC Is a Pure Play on Global Cannabis Normalization
As more countries legalize:

Medical markets expand

Adult-use markets open

Export markets grow

Pharmaceutical demand increases

CGC is positioned to benefit at every stage.

🚀 15. CGC Is Built for the Next Decade of Cannabis Growth
If you believe:

Cannabis will be federally legal

Global markets will open

U.S. brands will dominate

Edibles and vapes will explode

Medical cannabis will expand

…then CGC is one of the clearest, purest ways to express that view.

🌟 16. CGC Has the Brand Power, Global Reach, and U.S. Strategy to Become a Cannabis Giant
This is why bulls see massive long-term potential. $CGC $WEED

$WEED $CGC CGC Stock: Why This Turnaround Play Looks Deeply Undervalued & Ready to Rip
Keywords: CGC stock, CGC analysis, undervalued stocks, turnaround stocks, high-growth equities, bullish thesis, market catalysts, value investing, restructuring story, breakout stocks, macro tailwinds.

🌟 CGC Is Quietly Becoming One of the Most Undervalued Turnaround Plays in the Market
CGC has spent the last several years restructuring, cutting costs, and repositioning itself for long-term growth. Yet the stock still trades as if nothing has changed. That disconnect is exactly where asymmetric opportunities come from.

Investors scanning Yahoo Finance algos will notice the same pattern:

📉 Price depressed

📈 Forward outlook improving

🔄 Cost structure reset

💡 Optionality not priced in

This is the classic setup for a deep-value rebound.

🔧 Massive Restructuring = Leaner, Stronger, More Efficient
CGC has aggressively streamlined operations, exited non-core segments, and focused on higher-margin categories. The result is a company with:

Lower operating expenses

A simplified business model

Improved efficiency

A clearer path toward profitability

Yet the market still values it like the old, bloated version. That’s where the opportunity lies.

🌍 Global Expansion Tailwinds Are Not Priced In
CGC has positioned itself to benefit from international regulatory momentum. As more countries modernize their frameworks, companies with established infrastructure and brand reach gain the most.

CGC stands out because it has:

Cross-border distribution capabilities

Strategic partnerships

Scalable infrastructure

This gives it leverage that smaller competitors simply can’t match.

🇺🇸 U.S. Optionality = Hidden Value
Even incremental U.S. regulatory progress—banking reform, rescheduling, or state-level expansion—could unlock enormous value.

Right now, the market is pricing this optionality at zero, which is unrealistic given the direction of policy discussions.

This is a major catalyst hiding in plain sight.

📊 Yahoo Finance Algos Flag the Same Pattern
When you look at algorithmic indicators on Yahoo Finance, you see:

RSI oversold zones

High short interest (fuel for a squeeze)

Improving balance sheet metrics

Stabilizing revenue trends

Positive revisions in forward estimates

These are the exact signals algos look for when identifying undervalued turnaround candidates.

🔥 Why CGC Looks Bullish Right Now
Here’s the synthesis:

The company is leaner than ever

The cost base has been reset

International expansion is accelerating

U.S. optionality is still massively underpriced

Market sentiment is overly pessimistic

Technicals show accumulation at the bottom

This is the type of setup where sentiment can flip fast.

💎 Bottom Line: CGC Looks Like a High-Upside, Deep-Value Opportunity
CGC is priced for failure but positioned for recovery.
That’s the exact moment when asymmetric upside appears.

🌍 Global Cannabis Market Value & Growth Outlook
📈 Explosive Market Expansion
Across multiple independent industry forecasts, the cannabis market is growing at double-digit to high-double-digit annual rates, depending on the segment and methodology.

Here are the most authoritative figures:

$102.7B global market value in 2025, projected to reach $1.43 trillion by 2034 at a 34% CAGR.

Another global model estimates $14.1B in 2024, growing to $70.17B by 2034 at 17.4% CAGR.

A third forecast projects $134B in 2026, rising to $831B by 2035 at a 34% CAGR.

Additional analysis shows $38B in 2025, expected to reach $179.9B by 2034 at 18.8% CAGR.

Another long-term model projects $38.8B in 2025 growing to $159.8B by 2035 at 15.2% CAGR.

Synthesis:
Even though methodologies differ, every major forecast agrees:
➡️ Cannabis is one of the fastest-growing global industries, with projected growth ranging from 15% to 34% annually over the next decade.

🌎 Where Demand Is Coming From
🇺🇸 North America Leads
North America accounts for 40–84% of global market share depending on the model.

The U.S. alone is projected to reach over $428B by 2032 in some forecasts.

Recreational use drives 52–56% of U.S. demand, while medical use accounts for 42–44%.

🇪🇺 Europe Rising
Europe contributes 25–28% of global growth.

Medical cannabis adoption is accelerating due to regulatory reforms and healthcare integration.

🌏 Asia-Pacific Emerging
Asia-Pacific accounts for 20–21% of global growth.

Thailand’s full decriminalization in 2022 accelerated regional momentum.

🌍 Middle East, Africa & Latin America
These regions collectively contribute 10% of global growth.

Many countries are legalizing medical cannabis and exploring cannabis-based economic development.

💡 What’s Driving Global Demand?
1️⃣ Legalization Momentum
Over 50+ countries now allow medical cannabis, and many are moving toward recreational frameworks.

2️⃣ Medical Adoption
Cannabis is increasingly used for:

chronic pain

neurological disorders

cancer-related symptoms

appetite stimulation

anxiety and sleep disorders

3️⃣ Consumer Wellness Trends
58% of consumers prefer natural cannabis-based wellness products.

Edibles, oils, and concentrates are rapidly growing categories.

4️⃣ Product Innovation
Growth in edibles, beverages, skincare, and pharmaceutical formulations.

30% of new innovation comes from edibles and skincare.

5️⃣ Economic Opportunity
Cannabis legalization boosts job creation and tax revenue.

Many countries view cannabis as a strategic agricultural and pharmaceutical sector.

🔮 Bottom Line
Global cannabis demand is accelerating, driven by legalization, medical acceptance, wellness trends, and product innovation. Depending on the model, the market is on track to reach $150B to over $1.4T within the next decade. $CGC $WEED

The cannabis sector has some of the strongest long-term bullish forces of any emerging industry, driven by legalization momentum, massive consumer demand, and explosive market growth projections.

Below is a structured, deeply grounded, highly bullish outlook on cannabis stocks in general, with all claims supported by current industry data.

🌱 Why the Cannabis Sector Has Enormous Bullish Potential
1. Legalization Momentum Is Accelerating
The U.S. cannabis market is already enormous and is projected to grow at 11.5% annually through 2030, driven by expanding medical and recreational legalization.

Rescheduling efforts at the federal level have gained traction, with executive action pushing cannabis toward Schedule III, a shift industry leaders call a “game changer.”

More states are preparing to legalize adult-use markets, with large states like Florida and Pennsylvania expected to significantly boost national sales.

Bullish takeaway: Regulatory barriers are falling, and every new state that legalizes adds billions in potential revenue.

2. The Market Size Is Massive — and Growing Fast
The U.S. cannabis market was valued at $38.5 billion in 2024 and is projected to expand rapidly through 2030.

Global cannabis markets are even more explosive, expected to grow from $137.7 billion in 2026 to over $1.4 trillion by 2034 — a staggering 34% CAGR.

U.S. regulated cannabis sales alone are forecast to reach $39.1 billion by 2029.

Bullish takeaway: Few industries on Earth have trillion-dollar trajectories with this level of consumer demand and regulatory tailwinds.

3. Consumer Demand Is Deep, Diverse, and Expanding
Nearly half of U.S. adults have tried cannabis, reflecting broad cultural acceptance.

Demand spans medical, wellness, recreational, and specialty products — from flower to edibles to vapes to minor cannabinoids like CBN and CBG.

Pre-rolls and convenient formats are experiencing double-digit growth as mainstream consumers enter the market.

Bullish takeaway: Cannabis is no longer niche — it’s a normalized consumer category with accelerating adoption.

4. Medical Cannabis Is a Major Long-Term Growth Engine
Cannabis is increasingly used for chronic pain, chemotherapy-related nausea, and seizure disorders.

FDA-approved cannabis-derived medications (like Epidiolex) validate the plant’s therapeutic value.

As research expands, new medical applications will unlock additional multi-billion-dollar markets.

Bullish takeaway: Medical cannabis is still in early innings, with huge upside as clinical research expands.

5. Institutional Capital and Startups Are Flooding In
Major investment funds and private equity groups are deploying capital into cannabis infrastructure, cultivation, and retail.

Startups continue to raise large rounds, including $350 million+ financings for cannabis tech platforms.

Bullish takeaway: Smart money is positioning early for the next decade of growth.

6. International Legalization Is Creating a Global Opportunity
Countries across Europe, Asia, and Latin America are moving toward medical or recreational legalization.

Thailand’s full decriminalization of cannabis cultivation and consumption demonstrates how quickly markets can open and scale.

Bullish takeaway: Cannabis is becoming a global commodity, not just a U.S. trend.

🌿 Final Bullish Summary
The cannabis industry is supported by explosive market growth, broad consumer adoption, medical validation, and rapid legalization momentum. Despite short-term volatility, the long-term trajectory is unmistakably upward. The combination of regulatory reform, cultural acceptance, and trillion-dollar global potential makes cannabis one of the most compelling emerging sectors of the next decade. $WEED $CGC $SNDL

You don't have too be a Company or a million dollar Corporation too produce Cannabis it could be you, I won't pay a dollar for over priced, low quality ditch weed, you do know that Canadian cannabis businesses are bankrupt, have million dollar CEOs, and anyone that smokes more then 2 joints a day can't afford too supply themselves never mind Medical patients like myself. You can grow 4 plants that will keep your 4 month supply in rotation or 4 plant summer outdoor garden and you pay very little cost and a years supply. So now you know about the lies and bullshit from Corp weed, will you mark down too $2.95 a gram?
.

$WEED 🌿 CGC Product Lineup (All Verified Products)
According to multiple sources, Canopy Growth produces and sells a wide range of cannabis and wellness products across Canada, Germany, Australia, and other international markets.

1. Dried Cannabis Flower
Premium, mid-tier, and value flower sold under brands like Tweed, 7ACRES, DOJA, HiWay, Twd., Maitri, Vert, and more.
Market demand: Flower remains the largest global cannabis category.
Market worth: Global legal cannabis market projected to reach tens of billions annually.

2. Pre-Rolled Joints
Ready-to-use pre-rolls across multiple brands.
Demand: Fastest-growing convenience segment.
Market worth: Multi-billion global category.

3. Cannabis Oils & Softgel Capsules
Medical-grade oils and capsules sold under Spectrum Therapeutics and Canopy Medical.
Demand: Strong in medical markets (Germany, Canada).
Market worth: Medical cannabis is a multi-billion-dollar global sector.

4. Extracts & Concentrates
Includes vapes, distillates, and high-potency extracts.
Demand: High among adult-use consumers seeking potency.
Market worth: Concentrates are a multi-billion-dollar global category.

5. Edibles (Gummies, Chocolates, etc.)
Sold under brands like Wana, Deep Space, and Tweed.
Demand: Edibles are one of the fastest-growing segments.
Market worth: Billions globally, expanding rapidly.

6. Cannabis Beverages
THC-infused drinks under Deep Space and Tweed beverage lines.
Demand: Rising as consumers shift from alcohol to cannabis beverages.
Market worth: Expected to become a multi-billion-dollar global category.

7. Vapes & Vape Cartridges
A major product line across multiple brands.
Demand: Strong among adult-use consumers.
Market worth: Billions globally.

8. Storz & Bickel Vaporizers
High-end, globally recognized vaporizer hardware (Volcano, Mighty, Crafty).
Demand: Worldwide premium consumer base.
Market worth: Vaporizer hardware is a billion-dollar global market.

9. Topicals & Wellness Products
Sold under This Works, LivRelief, and other wellness brands.
Demand: Growing interest in cannabis-infused wellness.
Market worth: Global CBD/wellness market worth tens of billions.

🌍 Why CGC’s Markets Are So Valuable
CGC operates across medical, recreational, wellness, and hardware markets — giving it exposure to nearly every major cannabis revenue stream.

Global Cannabis Market Outlook
Legal cannabis market projected to exceed $100B+ globally over the next decade.

U.S. regulatory momentum (Schedule III reclassification) is creating massive upside.

CGC is positioned in Canada, Germany, Australia, and the U.S. — all high-value markets.

Brand Power
CGC owns some of the most recognized brands in cannabis:
Tweed, 7ACRES, DOJA, Wana, Storz & Bickel, Spectrum Therapeutics, and more.

Brand strength = pricing power + customer loyalty.

🚀 Bullish Takeaway
CGC has one of the broadest product portfolios in the global cannabis industry, and every product category it sells is part of a multi-billion-dollar market with accelerating demand.
With U.S. regulatory momentum and international expansion, CGC is positioned for significant upside as global cannabis adoption accelerates.

🌿🚀 300 Reasons Why $CGC (Canopy Growth) Is SUPER BULLISH $WEED
🌱 Canopy Growth Is a Global Cannabis Pioneer
CGC is one of the first major cannabis companies.

First movers dominate new industries.

CGC has global brand recognition.

CGC has international distribution.

CGC has operations in multiple continents.

CGC has medical cannabis operations.

CGC has recreational cannabis operations.

CGC has pharmaceutical-grade production.

CGC has EU-GMP certification.

EU-GMP allows global exports.

CGC is positioned for worldwide legalization.

Global legalization is accelerating.

CGC is early.

Early = massive upside.

CGC is a cannabis pioneer.

Pioneers become industry leaders.

CGC is building global infrastructure.

Infrastructure = long-term dominance.

CGC is a global cannabis titan.

CGC is built for global scale.

🇺🇸 Canopy Growth Has a Direct Path Into the U.S. Market
CGC owns Canopy USA.

Canopy USA gives CGC U.S. exposure.

U.S. cannabis is the biggest market in the world.

U.S. legalization is inevitable.

CGC is positioned to enter instantly.

CGC owns U.S. brands.

CGC owns Wana Brands.

Wana is the #1 edibles brand in North America.

CGC owns Jetty Extracts.

Jetty is a top vape brand.

CGC owns Acreage.

Acreage gives CGC U.S. retail access.

CGC has a U.S. multi-state footprint ready to activate.

CGC is the most U.S.-ready Canadian LP.

U.S. legalization = rocket fuel.

CGC will dominate infused beverages.

CGC will dominate edibles.

CGC will dominate vapes.

CGC will dominate wellness.

CGC is the U.S. legalization trade.

🍺 Canopy Growth Has a Massive Partnership With Constellation Brands
Constellation Brands invested billions in CGC.

Constellation owns Corona, Modelo, and more.

Constellation is a beverage giant.

Beverage giants don’t invest lightly.

Constellation validated CGC’s potential.

Constellation gives CGC global distribution.

Constellation gives CGC beverage expertise.

Constellation gives CGC brand power.

Constellation gives CGC financial backing.

Constellation gives CGC credibility.

Cannabis beverages will be huge.

CGC + Constellation = beverage dominance.

CGC is the global leader in cannabis drinks.

Cannabis drinks are the future.

CGC is positioned perfectly.

Constellation partnership is a moat.

Moats create long-term winners.

CGC is a long-term winner.

CGC is the beverage-cannabis hybrid giant.

CGC is the future of infused beverages.

💊 Canopy Growth Dominates Medical Cannabis
CGC supplies medical cannabis globally.

Medical cannabis demand is rising.

Doctors are prescribing cannabis more often.

Patients prefer natural treatments.

CGC produces pharmaceutical-grade products.

CGC has clinical-grade facilities.

CGC has medical partnerships.

CGC has research collaborations.

CGC has medical distribution channels.

CGC is trusted by physicians.

Medical cannabis is high-margin.

High-margin = high profitability.

CGC is positioned for medical expansion.

Medical legalization is accelerating globally.

CGC is the global medical leader.

Medical cannabis is a long-term megatrend.

CGC is aligned with that megatrend.

Megatrends create massive winners.

CGC is one of them.

CGC is the medical cannabis brand of the future.

🌍 Canopy Growth Has Global Reach
CGC exports to Europe.

CGC exports to Australia.

CGC exports to Latin America.

CGC exports to Israel.

CGC exports to international pharmacies.

CGC has global supply chains.

CGC has global logistics.

CGC has global partnerships.

CGC has global cultivation.

CGC has global processing.

CGC has global packaging.

CGC has global compliance.

CGC is everywhere cannabis is legal.

CGC will be everywhere cannabis becomes legal.

Global legalization is accelerating.

CGC is positioned to capture global demand.

Global demand is enormous.

CGC’s TAM is global.

Global TAM = massive upside.

CGC is a global cannabis empire.

🧪 Canopy Growth Has World-Class R&D
CGC invests heavily in research.

CGC develops new strains.

CGC develops new formulations.

CGC develops new delivery methods.

CGC develops new medical applications.

CGC develops new consumer products.

CGC’s R&D team is elite.

CGC’s innovation pipeline is strong.

Innovation drives adoption.

Adoption drives revenue.

Revenue drives valuation.

CGC is innovating aggressively.

CGC is creating next-gen cannabis products.

CGC is creating next-gen beverages.

CGC is creating next-gen wellness products.

CGC is creating next-gen medical products.

CGC is building the future of cannabis.

The future of cannabis is enormous.

CGC is positioned to lead it.

CGC is the innovation engine of cannabis.

🏭 Canopy Growth Has Massive Production Capacity
CGC has huge cultivation facilities.

CGC has high-tech greenhouses.

CGC has automated production.

CGC has scalable operations.

CGC has efficient processing.

CGC has advanced extraction.

CGC has pharmaceutical-grade labs.

CGC has global supply chains.

CGC has massive output potential.

CGC can scale instantly.

Scaling = revenue growth.

Revenue growth = valuation growth.

CGC’s infrastructure is unmatched.

CGC’s production is world-class.

CGC’s facilities are state-of-the-art.

CGC’s capacity is expanding.

CGC is ready for global demand.

Global demand is rising.

CGC is positioned perfectly.

CGC is built for scale.

🛒 Canopy Growth Has Powerful Consumer Brands
CGC owns multiple cannabis brands.

CGC owns multiple wellness brands.

CGC owns multiple lifestyle brands.

CGC owns multiple medical brands.

CGC’s brands are growing.

CGC’s brands are recognized.

CGC’s brands are trusted.

CGC’s brands are expanding.

CGC’s brands appeal to young consumers.

CGC’s brands appeal to wellness consumers.

CGC’s brands appeal to recreational consumers.

CGC’s brands appeal to medical consumers.

CGC’s brands appeal to global consumers.

CGC’s brand portfolio is diversified.

Diversification = stability.

Stability = long-term growth.

CGC is building a consumer-goods empire.

Cannabis + beverages = unstoppable.

CGC is the Procter & Gamble of cannabis.

CGC is building a consumer powerhouse.

📈 Canopy Growth Has Massive Growth Potential
Cannabis demand is rising.

Beverage demand is rising.

Wellness demand is rising.

Global legalization is rising.

Medical adoption is rising.

Recreational adoption is rising.

CGC is positioned for all of it.

CGC’s TAM is enormous.

TAM expansion = valuation expansion.

CGC is early in its growth curve.

Early = asymmetric upside.

Asymmetric upside = moonshot potential.

CGC is a long-term compounder.

Compounders create massive returns.

CGC is a global growth story.

CGC is a U.S. legalization story.

CGC is a cannabis beverage story.

CGC is a wellness story.

CGC is a consumer-goods story.

CGC is a multi-sector growth engine.

🌋 Canopy Growth Is Positioned for Explosive Expansion
CGC is expanding in Europe.

CGC is expanding in the U.S.

CGC is expanding in Canada.

CGC is expanding in Australia.

CGC is expanding in Latin America.

CGC is expanding in Israel.

CGC is expanding globally.

Expansion = revenue growth.

Revenue growth = valuation growth.

CGC is scaling fast.

CGC is acquiring brands.

CGC is consolidating the industry.

CGC is building a global empire.

CGC is becoming a multinational giant.

CGC is positioned for hypergrowth.

Hypergrowth = massive upside.

CGC is a global cannabis titan.

CGC is a global beverage titan.

CGC is a global wellness titan.

CGC is a global consumer titan.

🔮 Canopy Growth Is Building the Future of Cannabis
The future is cannabis beverages.

CGC is ready for that.

The future is cannabis wellness.

CGC is ready for that.

The future is cannabis pharmaceuticals.

CGC is ready for that.

The future is global legalization.

CGC is ready for that.

The future is infused drinks.

CGC is ready for that.

The future is cannabis tourism.

CGC is ready for that.

The future is cannabis retail.

CGC is ready for that.

The future is cannabis branding.

CGC is ready for that.

The future is cannabis distribution.

CGC is ready for that.

The future is cannabis consumer goods.

CGC is ready for that.

🌠 Canopy Growth’s Long-Term Potential Is Enormous
CGC could dominate global cannabis.

CGC could dominate infused beverages.

CGC could dominate cannabis wellness.

CGC could dominate cannabis pharma.

CGC could dominate cannabis retail.

CGC could dominate cannabis branding.

CGC could dominate cannabis distribution.

CGC could dominate cannabis edibles.

CGC could dominate cannabis lifestyle products.

CGC could become a global giant.

CGC could become a household name.

CGC could become a consumer-goods empire.

CGC could become a beverage empire.

CGC could become a cannabis empire.

CGC could become a multinational titan.

CGC could become a generational company.

Generational companies create generational wealth.

CGC is early.

Early = opportunity.

Opportunity = upside.

🌞 Canopy Growth Is a Once-in-a-Generation Cannabis Company
CGC is a global leader.

CGC is diversified.

CGC is innovative.

CGC is expanding.

CGC is scaling.

CGC is acquiring.

CGC is dominating.

CGC is building.

CGC is evolving.

CGC is transforming.

CGC is shaping the future.

CGC is aligned with megatrends.

CGC is aligned with legalization.

CGC is aligned with wellness.

CGC is aligned with beverages.

CGC is aligned with global growth.

CGC is aligned with consumer demand.

CGC is aligned with the future.

CGC is a future giant.

CGC is a future empire.

🚀 Canopy Growth Is a Multi-Sector Moonshot
Cannabis is a megatrend.

Beverages are a megatrend.

Wellness is a megatrend.

Global legalization is a megatrend.

CGC is in all of them.

Multi-megatrend exposure = massive upside.

CGC is a multi-sector disruptor.

Disruptors create massive returns.

CGC is early in its disruption curve.

Early = asymmetric upside.

Asymmetric upside = moonshot.

CGC is a moonshot.

Moonshots change industries.

CGC will change cannabis.

CGC will change beverages.

CGC will change wellness.

CGC will change consumer goods.

CGC will change global markets.

CGC is a global disruptor.

CGC is a global innovator.

🌌 Canopy Growth’s Story Is Just Beginning
CGC is early-stage.

Early-stage = maximum upside.

CGC is pre-U.S. legalization.

Pre-legalization = explosive potential.

CGC is pre-infused beverage boom.

Pre-boom = massive runway.

CGC is pre-global cannabis adoption.

Pre-adoption = exponential growth.

CGC is pre-mainstream cannabis acceptance.

Pre-mainstream = generational upside.

CGC is building infrastructure.

Infrastructure = long-term dominance.

CGC is building brands.

Brands = long-term value.

CGC is building global reach.

Global reach = global revenue.

CGC is building the future.

The future is cannabis.

The future is beverages.

The future is CGC — and that’s as bullish as it gets.

Canopy Growth jumps as U.S. moves to ease medical marijuana restrictionsApril 23, 2026 10:55 AM
IH Market News
Shares of cannabis companies rallied in premarket trading on Thursday after a major regulatory shift in the United States signaled a more favorable environment for the sector, with Canopy Growth Corp (NASDAQ:CGC) among the notable gainers.The move follows news that the acting U.S. attorney general signed an order to reclassify state-licensed medical marijuana, shifting it from Schedule I to Schedule III under federal law.



Regulatory shift seen as major catalyst



The reclassification is expected to significantly reduce regulatory hurdles for licensed operators, while also unlocking tax advantages that could improve profitability across the industry.The change is also viewed as a step toward expanding patient access to medical cannabis treatments across the roughly 40 U.S. states where such use is already legal.



Investor optimism lifts cannabis stocks



The announcement sparked a positive reaction across the cannabis sector, with investors betting the lighter regulatory framework could drive stronger revenues and accelerate growth for key players.Canopy Growth, one of the most closely watched names in the space, has struggled in recent years, but the new policy direction is seen as a potential turning point for the company.



Company profile and financial snapshot



Canopy Growth operates as a major producer and distributor of both medical and recreational cannabis, with brands including Tweed and Bedrocan.The company currently has a market capitalization of approximately $585 million. Its GF Score stands at 54/100, suggesting moderate long-term return potential, while its financial strength rating of 4/10 highlights ongoing balance sheet challenges.



Outlook for the sector



The shift to Schedule III is expected to ease compliance costs and improve access to banking and tax efficiencies, which could materially benefit cannabis operators.For companies like Canopy Growth, the evolving regulatory backdrop may provide a much-needed boost as the industry looks to stabilize and return to growth.Canopy Growth Corp stock price

Original: Canopy Growth jumps as U.S. moves to ease medical marijuana restrictions

Canadian Investment Regulatory Organization Trading Halt - WEEDApril 22, 2026 12:00 PM
PR Newswire (Canada)

TORONTO, April 22, 2026 /CNW/ - The following issues have been halted by CIRO:Company: Canopy Growth CorporationTSX Symbol: WEEDAll Issues: NoReason: Single Stock Circuit BreakerHalt Time (ET): 11:50:02 AMCIRO can make a decision to impose a temporary suspension (halt) of trading in a security of a publicly-listed company. Trading halts are implemented to ensure a fair and orderly market. CIRO is the national self-regulatory organization which oversees all investment dealers and trading activity on debt and equity marketplaces in Canada.SOURCE Canadian Investment Regulatory Organization (CIRO) – Halts/Resumptions

Original: Canadian Investment Regulatory Organization Trading Halt - WEED

Suspension de la négociation par l'Organisme canadien de réglementation des investissements - WEEDApril 22, 2026 12:02 PM
PR Newswire (Canada)

TORONTO, le 22 avril 2026 /CNW/ - L'OCRI a suspendu la négociation des titres suivants :Société : Canopy Growth CorporationSymbole TSX : WEEDLes titres : NonMotif : Coupe-circuits pour titre individuelHeure de la suspension (HE) : 11 h 50:02L'OCRI peut prendre la décision de suspendre (ou d'arrêter) temporairement les opérations à l'égard d'un titre d'une société cotée en bourse. Les arrêts des opérations sont mis en oeuvre afin d'assurer le bon fonctionnement d'un marché équitable. L'OCRI est l'organisme d'autoréglementation national qui surveille l'ensemble des courtiers en placement et l'ensemble des opérations effectuées sur les marchés des titres de capitaux propres et les marchés des titres de créance au Canada.SOURCE L’Organisme canadien de règlementation des investissements (OCRI) - Arrêts/Reprises

Original: Suspension de la négociation par l'Organisme canadien de réglementation des investissements - WEED

Canadian Investment Regulatory Organization Trade Resumption - WEEDApril 22, 2026 12:06 PM
PR Newswire (Canada)

TORONTO, April 22, 2026 /CNW/ - Trading resumes in:Company: Canopy Growth CorporationTSX Symbol: WEEDAll Issues: NoResumption (ET): 11:55:02 AMCIRO can make a decision to impose a temporary suspension (halt) of trading in a security of a publicly-listed company. Trading halts are implemented to ensure a fair and orderly market. CIRO is the national self-regulatory organization which oversees all investment dealers and trading activity on debt and equity marketplaces in Canada..SOURCE Canadian Investment Regulatory Organization (CIRO) – Halts/Resumptions

Original: Canadian Investment Regulatory Organization Trade Resumption - WEED

L'Organisme canadien de réglementation des investissements permet la reprise de la négociation - WEEDApril 22, 2026 12:08 PM
PR Newswire (Canada)

TORONTO, le 22 avril 2026 /CNW/ - Reprise des négociations pour :Société : Canopy Growth CorporationSymbole TSX : WEEDLes titres : NonReprise : 11 h 55:02L'OCRI peut prendre la décision de suspendre (ou d'arrêter) temporairement les opérations à l'égard d'un titre d'une société cotée en bourse. Les arrêts des opérations sont mis en oeuvre afin d'assurer le bon fonctionnement d'un marché équitable. L'OCRI est l'organisme d'autoréglementation national qui surveille l'ensemble des courtiers en placement et l'ensemble des opérations effectuées sur les marchés des titres de capitaux propres et les marchés des titres de créance au Canada.SOURCE L’Organisme canadien de règlementation des investissements (OCRI) - Arrêts/Reprises

Original: L'Organisme canadien de réglementation des investissements permet la reprise de la négociation - WEED

🔥 10 Reasons Why $CGC Could Double Soon
1. Canopy Is on the Verge of U.S. Market Entry
Canopy Growth has created Canopy USA, a structure designed to acquire U.S. cannabis assets the moment federal rules allow it.
This includes stakes in:

Acreage Holdings

Wana Brands

Jetty Extracts

If the U.S. opens even partially, CGC becomes one of the first Canadian LPs with immediate U.S. exposure.

That’s a massive rerating catalyst.

2. Federal Cannabis Reform Is Heating Up
Any of the following could ignite a major rally:

Rescheduling

SAFE Banking

Descheduling discussions

Executive-branch policy shifts

Congressional hearings

Cannabis stocks historically explode on regulatory momentum — and CGC is one of the most liquid names in the sector.

3. Canopy Has Completed a Major Restructuring
CGC has aggressively:

Cut costs

Reduced debt

Streamlined operations

Exited unprofitable segments

Consolidated production

This is the foundation of every successful turnaround story.

4. The Company Is Pivoting Toward Profitability
Canopy has shifted from “growth at all costs” to:

Margin expansion

Cash preservation

High-value product focus

When a cannabis company pivots to profitability, the market reacts fast.

5. Strong Brand Portfolio With Real Consumer Recognition
Canopy owns or controls:

Tweed

Wana

Jetty

Storz & Bickel

BioSteel (legacy brand)

These are some of the most recognized names in cannabis and accessories.

Brand power matters — especially when the sector rebounds.

6. Storz & Bickel Is a Quiet Cash Machine
The Volcano and Mighty vaporizers are premium, globally recognized products with strong margins.
This segment alone gives CGC a revenue base that many cannabis companies lack.

7. CGC Is Deeply Oversold
The stock trades at levels that imply the company has no future.
But CGC still has:

Global distribution

Strong brands

U.S. entry optionality

A real restructuring plan

Oversold + real assets = explosive rebound potential.

8. High Short Interest = Fuel
CGC consistently carries elevated short interest.
When sentiment shifts, heavily shorted cannabis names can move sharply.

A single positive catalyst can trigger a powerful upside wave.

9. Global Medical Cannabis Is Growing Fast
Canopy has a strong presence in:

Canada

Germany

Australia

U.K.

Other medical markets

Medical cannabis is expanding globally — and CGC is positioned to benefit.

10. One Major Catalyst Can Reprice the Stock Overnight
Any of the following could spark a major rally:

U.S. regulatory progress

Canopy USA activation

A major partnership

Strong earnings

New product launches

International expansion

Short-covering wave

CGC is a catalyst-driven stock — and it has multiple shots on goal.

⭐ The Bullish Summary
$CGC is a high-potential cannabis + consumer-goods + U.S.-entry play with:

A unique U.S. market strategy

Strong global brands

Major restructuring progress

Oversold valuation

High short interest

Multiple regulatory catalysts

Real international growth

If sentiment flips, Canopy Growth has the structure and leverage to move sharply.

🌿 Canopy Growth ($CGC) — Full Product Lineup
1. Cannabis Flower (High-THC & Premium Genetics)
Canopy Growth produces and sells a wide range of medical and recreational cannabis flower, including new high-potency strains.
Examples from current launches:

Blood Orange Kush (Tweed) — >28% THC

Sour Sucker Mints (Tweed) — >28% THC

Blue Dream (7ACRES)

Jack Haze (7ACRES)

These are sold in 7g and 28g formats.

2. Pre-Rolls (Including Infused)
Part of their focused strategy on high-demand adult-use formats:

Standard pre-rolls

Infused pre-rolls
Available across brands like Tweed, 7ACRES, Claybourne, and Deep Space.

3. Vapes & Vaporization Devices
A. All-in-One (AIO) Vapes
Using CCELL advanced hardware with display screens and variable voltage.
Tweed AIO vapes (0.95g liquid diamond):

Gorilla Berry Grape

Blood Orange Kush

Kush Mints

7ACRES AIO vapes (0.95g live resin + liquid diamonds):

Blue Dream

Jack Haze

B. Storz & Bickel Devices
Canopy owns Storz & Bickel, makers of category-defining vaporizers:

Volcano

Mighty / Mighty+

Crafty+

Plenty
These are part of CGC’s dedicated Storz & Bickel segment.

4. Edibles
Edibles are a core format in their adult-use strategy.

Deep Space edibles (brand returning to the category)

Additional gummies and edible products under Tweed and other brands

5. Oils, Capsules & Medical Cannabis Products
Canopy Growth sells a full suite of medical cannabis products globally:

Cannabis oils

Softgels / capsules

Dried flower for medical patients

Cannabinoid-based formulations
These are distributed under brands like Spectrum, Tweed, and Bedrocan heritage lines.

6. Hemp & CBD Products
Part of their Canadian cannabis segment includes:

Hemp-derived products

CBD wellness products

7. Brand Portfolio (Product Families)
Canopy’s products are sold under a large multi-brand ecosystem:

Tweed

7ACRES

DOJA

Deep Space

Claybourne

Storz & Bickel

Summary — Everything CGC Makes
Cannabis Products:

High-THC flower

Pre-rolls & infused pre-rolls

Edibles (Deep Space, Tweed, etc.)

Oils, capsules, medical cannabis

Hemp & CBD products

Vapes & Devices:

AIO vapes (Tweed, 7ACRES)

Storz & Bickel premium vaporizers (Volcano, Mighty+, Crafty+, Plenty)

Brands:
Tweed, 7ACRES, DOJA, Deep Space, Claybourne, Storz & Bickel

🌿 $CGC — Canopy Growth: A Global Cannabis Innovator With Iconic Brands
Canopy Growth Corporation ($CGC) is one of Canada’s most recognized cannabis companies, producing and distributing a wide portfolio of cannabis, hemp, and cannabis-related products across Canada, Germany, Australia, and international markets. Headquartered in Smiths Falls, Ontario, the company has evolved from its origins as Tweed Marijuana Inc. into a diversified global cannabis and wellness powerhouse.

Operating through four major segments — Canada Cannabis, International Markets Cannabis, Storz & Bickel, and This Works — Canopy Growth delivers a wide range of products including dried flower, pre-rolls, softgel capsules, extracts, vapes, edibles, oils, beverages, and concentrates. Its brand ecosystem is one of the strongest in the industry, featuring well-known names such as Tweed, 7ACRES, Deep Space, HiWay, Maitri, Twd., Spectrum Therapeutics, Wana, Storz & Bickel, DOJA, LivRelief, Ace Valley, Vert, and more.

Canopy Growth also owns Storz & Bickel, the world-renowned manufacturer of premium vaporization devices, and This Works, a wellness and skincare brand — expanding its reach beyond cannabis into lifestyle and consumer health.

Founded in 2013 and renamed in 2015, Canopy Growth became the first federally regulated, publicly traded cannabis producer in North America, marking a major milestone in the global cannabis industry. Today, it continues to innovate across medical, recreational, and wellness markets, supported by a diverse brand portfolio and international distribution network.

🌿🔥 20 Reasons Why $CGC Could Quadruple in 2026
Below are 20 fact-supported catalysts, each tied to real financial data or management commentary from the latest filings and earnings calls.

📈 1. Cannabis revenue up 24% YoY
CGC’s cannabis segment posted 24% year-over-year growth, driven by strong Canadian adult-use and medical demand.

🍁 2. Canada adult-use revenue up 43% YoY
This is one of the strongest growth rates among major LPs.

🌍 3. International medical cannabis expansion
Management highlighted supply-chain improvements and margin-accretive European markets ramping in FY2026.

🧪 4. Storz & Bickel remains a premium global brand
CGC’s vaporizer division is now a standalone reporting segment, reflecting its strategic importance.

💰 5. SG&A down 21% YoY
Cost discipline is finally showing up in the numbers.

💸 6. $17M of $20M cost-savings already achieved
This materially improves the path to EBITDA profitability.

📦 7. Net revenue up 9% YoY
Q1 FY2026 revenue hit $72.1M, beating estimates and reversing years of contraction.

🧱 8. Cash position increased to $144M
Liquidity improved quarter-over-quarter — rare in this sector.

🧭 9. Management reaffirmed margin-recovery focus
CEO and CFO emphasized margin repair as the top priority.

🛒 10. Strong consumer demand for new products
Claybourne infused pre-rolls and other innovations are driving category share gains.

🧩 11. Two-segment structure increases transparency
Separating Cannabis + Storz & Bickel helps investors value each business more accurately.

🔄 12. Free cash flow improved 79% YoY
Still negative, but dramatically better than last year.

🧨 13. High short interest = squeeze potential
CGC is one of the most shorted cannabis names — any regulatory catalyst could trigger a violent re-rating.

🇩🇪 14. Germany’s legalization wave benefits CGC
CGC already has EU-GMP infrastructure and distribution via C3 and other assets.

🧠 15. Leadership with CPG experience
New CEO Luc Mongeau is executing a more disciplined, consumer-focused strategy.

🧬 16. Vaporizer innovation continues
A new Storz & Bickel device launches in late 2026 — historically, these launches drive strong revenue spikes.

🏦 17. Sector-wide catalysts: U.S. rescheduling + SAFE Banking
Any U.S. federal movement lifts all cannabis equities — CGC is one of the most liquid names.

📉 18. Trading near 52-week lows
With a 52-week range of $0.77–$2.38, the upside skew is enormous.

🧲 19. CGC remains a retail-favorite momentum stock
When cannabis sentiment flips, CGC historically leads ETF inflows and sector rallies.

🚀 20. Mean reversion after years of compression
CGC is down over 95% from its peak — surviving companies with real revenue often rebound sharply once fundamentals stabilize.

⭐ Why War & High Oil Prices Make Canopy Growth’s $CGC Products More Attractive
Canopy Growth is a diversified global cannabis company producing medical cannabis, recreational cannabis, hemp products, and high-end vaporizers.
During geopolitical instability and energy shocks, these product categories become more resilient, more in demand, and less exposed to oil-driven cost volatility.

🌿 1. Cannabis Demand Is Stable or Counter-Cyclical During Crises
CGC produces and sells cannabis across Canada, Germany, Australia, and other markets.

Why this matters
Cannabis demand remains steady even during economic or geopolitical stress.

Medical cannabis demand is especially resilient because patients rely on it for chronic conditions.

Cannabis is not tied to oil prices, unlike many consumer goods.

🧪 2. Medical Cannabis Demand Rises During Wartime Stress
CGC’s Spectrum Therapeutics division is a global leader in medical cannabis.

Why this matters
Wars increase PTSD, anxiety, chronic pain, and sleep disorders.

Medical cannabis becomes a more important therapeutic option.

Governments often expand access during crises to support public health.

🔥 3. Cannabis Production Is Less Oil-Dependent Than Traditional Consumer Goods
CGC produces cannabis in indoor and greenhouse facilities with GMP-certified operations.

Why this matters
Cannabis cultivation relies more on electricity than petroleum.

Rising oil prices have minimal impact on production costs compared to fuel-intensive industries.

This makes CGC’s cost structure more stable during energy shocks.

🌍 4. Global Footprint Reduces Geopolitical Risk
CGC operates in Canada, Germany, Australia, the U.S., and other countries.

Why this matters
A diversified geographic footprint reduces exposure to any single region affected by war.

CGC can shift supply between facilities in Canada, Europe, and Australia.

Cannabis distribution is less energy-intensive than heavy manufacturing.

💨 5. Storz & Bickel Vaporizers Are High-Margin, Non-Oil-Dependent Products
CGC owns Storz & Bickel, a global leader in premium cannabis vaporizers.

Why this matters
Vaporizers are durable goods with high margins.

Demand remains strong even during economic stress.

Production is not tied to oil markets, making margins more stable.

🌱 6. Hemp & CBD Products Avoid Oil-Driven Inflation
CGC sells hemp-derived CBD oils, softgels, and wellness products.

Why this matters
Hemp and CBD are agricultural, not petroleum-based.

They avoid the cost inflation seen in oil-linked consumer goods.

Wellness product demand increases during stressful geopolitical periods.

🏥 7. Pharmaceutical-Grade Cannabis Is Essential During Crises
CGC produces pharmaceutical-grade cannabis and cannabinoid-based products.

Why this matters
Medical supply chains are prioritized during war.

Pharmaceutical cannabis is considered essential for many patients.

This creates stable, recurring demand.

🛡️ 8. Cannabis Is a Domestic Industry in Canada & Germany
CGC’s core operations are in Canada and Germany—countries with stable domestic cannabis frameworks.

Why this matters
Domestic production avoids international shipping disruptions.

Cannabis is not reliant on global oil-based logistics.

Local supply chains remain intact even during geopolitical instability.

📈 9. Cannabis Legalization Momentum Often Increases During Economic Stress
Governments expand cannabis access to:

Increase tax revenue

Reduce law-enforcement costs

Stimulate job creation

CGC is positioned to benefit as a leading global cannabis company.

🧭 10. CGC’s Product Mix Is Naturally Resilient to Oil Price Volatility
CGC sells:

Dried flower

Pre-rolls

Edibles

Oils

Beverages

Vaporizers

Medical cannabis products

Why this matters
None of these categories rely heavily on petroleum.

Consumer demand for cannabis and wellness products is stable.

High-margin vaporizer sales help offset macroeconomic pressure.

📌 Summary Table: Why War & High Oil Prices Benefit CGC
CGC Product Segment Why It Gains Value During War & Oil Spikes Source
Medical cannabis Essential, rising demand during crises
Recreational cannabis Stable demand, not oil-dependent
Storz & Bickel vaporizers High-margin, durable, non-oil-linked
Hemp & CBD wellness Avoid oil-driven inflation
Global distribution Reduces geopolitical risk

⭐ Why War & High Oil Prices Make Canopy Growth’s $CGC Products More Attractive
Canopy Growth is a diversified global cannabis company producing medical cannabis, recreational cannabis, hemp products, and high-end vaporizers.
During geopolitical instability and energy shocks, these product categories become more resilient, more in demand, and less exposed to oil-driven cost volatility.

🌿 1. Cannabis Demand Is Stable or Counter-Cyclical During Crises
CGC produces and sells cannabis across Canada, Germany, Australia, and other markets.

Why this matters
Cannabis demand remains steady even during economic or geopolitical stress.

Medical cannabis demand is especially resilient because patients rely on it for chronic conditions.

Cannabis is not tied to oil prices, unlike many consumer goods.

🧪 2. Medical Cannabis Demand Rises During Wartime Stress
CGC’s Spectrum Therapeutics division is a global leader in medical cannabis.

Why this matters
Wars increase PTSD, anxiety, chronic pain, and sleep disorders.

Medical cannabis becomes a more important therapeutic option.

Governments often expand access during crises to support public health.

🔥 3. Cannabis Production Is Less Oil-Dependent Than Traditional Consumer Goods
CGC produces cannabis in indoor and greenhouse facilities with GMP-certified operations.

Why this matters
Cannabis cultivation relies more on electricity than petroleum.

Rising oil prices have minimal impact on production costs compared to fuel-intensive industries.

This makes CGC’s cost structure more stable during energy shocks.

🌍 4. Global Footprint Reduces Geopolitical Risk
CGC operates in Canada, Germany, Australia, the U.S., and other countries.

Why this matters
A diversified geographic footprint reduces exposure to any single region affected by war.

CGC can shift supply between facilities in Canada, Europe, and Australia.

Cannabis distribution is less energy-intensive than heavy manufacturing.

💨 5. Storz & Bickel Vaporizers Are High-Margin, Non-Oil-Dependent Products
CGC owns Storz & Bickel, a global leader in premium cannabis vaporizers.

Why this matters
Vaporizers are durable goods with high margins.

Demand remains strong even during economic stress.

Production is not tied to oil markets, making margins more stable.

🌱 6. Hemp & CBD Products Avoid Oil-Driven Inflation
CGC sells hemp-derived CBD oils, softgels, and wellness products.

Why this matters
Hemp and CBD are agricultural, not petroleum-based.

They avoid the cost inflation seen in oil-linked consumer goods.

Wellness product demand increases during stressful geopolitical periods.

🏥 7. Pharmaceutical-Grade Cannabis Is Essential During Crises
CGC produces pharmaceutical-grade cannabis and cannabinoid-based products.

Why this matters
Medical supply chains are prioritized during war.

Pharmaceutical cannabis is considered essential for many patients.

This creates stable, recurring demand.

🛡️ 8. Cannabis Is a Domestic Industry in Canada & Germany
CGC’s core operations are in Canada and Germany—countries with stable domestic cannabis frameworks.

Why this matters
Domestic production avoids international shipping disruptions.

Cannabis is not reliant on global oil-based logistics.

Local supply chains remain intact even during geopolitical instability.

📈 9. Cannabis Legalization Momentum Often Increases During Economic Stress
Governments expand cannabis access to:

Increase tax revenue

Reduce law-enforcement costs

Stimulate job creation

CGC is positioned to benefit as a leading global cannabis company.

🧭 10. CGC’s Product Mix Is Naturally Resilient to Oil Price Volatility
CGC sells:

Dried flower

Pre-rolls

Edibles

Oils

Beverages

Vaporizers

Medical cannabis products

Why this matters
None of these categories rely heavily on petroleum.

Consumer demand for cannabis and wellness products is stable.

High-margin vaporizer sales help offset macroeconomic pressure.

📌 Summary Table: Why War & High Oil Prices Benefit CGC
CGC Product Segment Why It Gains Value During War & Oil Spikes Source
Medical cannabis Essential, rising demand during crises
Recreational cannabis Stable demand, not oil-dependent
Storz & Bickel vaporizers High-margin, durable, non-oil-linked
Hemp & CBD wellness Avoid oil-driven inflation
Global distribution Reduces geopolitical risk

$WEED $CGC https://www.marijuanamoment.net/marijuana-rescheduling-could-be-impacted-if-trump-replaces-bondi-as-attorney-general-with-zeldin/

🍺🌿 Wartime economies often see rising demand for beer & cannabis as consumers lean on comfort markets. With global cannabis momentum building and alcohol sales steady, $CGC is positioned for a potential breakout as sentiment shifts. 📈🔥 $WEED

MJ – Amplify Alternative Harvest ETF
What it really focuses on

MJ is one of the oldest and best-known cannabis ETFs and is heavily tilted to Canadian LPs and global cannabis equities:

Top holdings include: TLRY, Cronos, Canopy Growth, SNDL, Village Farms, Aurora, High Tide, Organigram. TLRY is one of the largest positions by weight.

It also holds some ancillary and cash/treasury instruments, but the core is still LPs and cannabis-adjacent equities.

Why those stocks?

Legacy listing advantage: Canadian LPs were among the first cannabis names to list on major exchanges, so they became the natural core of early cannabis indices and ETFs like MJ.

Global optionality: LPs like TLRY, Cronos, and Canopy have international medical operations and partnerships, giving exposure to non-U.S. legalization trends.

Brand and CPG angle: TLRY and Canopy in particular are trying to pivot into branded consumer products (beverages, wellness, etc.), which MJ captures by holding them at size.

Market demand angle

Who buys MJ? Investors who want a simple, liquid, “brand-name” cannabis ETF and are okay with a big Canadian tilt.

Demand drivers:

Retail investors who recognize names like TLRY and CGC.

International investors who can more easily access Canadian LPs than U.S. MSOs.

Implication for TLRY: Because MJ is widely recognized, flows into or out of MJ can materially affect TLRY’s trading, given TLRY’s large weight in the fund. $WEED

Canopy Growth Unveils New Brand ‘Deelish’: High THC, Everyday PriceMarch 31, 2026 7:30 AM
Business Wire
27%-33% THC flower, and 26%-32% THC pre-rolls across rotating genetics


Now available at select stores across Ontario and Alberta


Canopy Growth Corporation (“Canopy Growth” or the “Company”) (TSX: WEED) (Nasdaq: CGC) today announced Deelish ("DEE-LISH"), a new cannabis brand built for the everyday consumer with an everyday price.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260331523789/en/High THC, Everyday Price. Deelish is Canopy Growth's newest brand, delivering high THC with flower testing at 27%-33% THC and pre-rolls at 26%-32% THC.
Deelish enters the market built to deliver high THC with flower testing at 27%-33% THC and pre-rolls at 26%-32% THC. And unlike brands built around a single profile, Deelish rotates its genetic lineup regularly, giving consumers access to a curated range of cultivars over time.


“The value segment is one of the most active parts of the Canadian cannabis market. Consumers know exactly what they want, and Deelish was made to deliver a high-potency product with a price that respects how they shop. This is a brand built on listening, and we’re confident it reflects where this market is going,” said Luc Mongeau, Chief Executive Officer, Canopy Growth.


Deelish launched with four SKUs across formats:


Pretty Sweet Sativa 28g Whole Flower | 27-33% THC


Pretty Sweet Sativa 2x1g Pre-roll Joints | 26-32% THC


Pretty Chill Indica 28g Whole Flower | 27-33% THC


Pretty Chill Indica 2x1g Pre-roll Joints | 26-32% THC


Now available at select stores across Ontario and Alberta.


About Canopy Growth


Canopy Growth is a world-leading cannabis company dedicated to unleashing the power of cannabis to improve lives.


Through an unwavering commitment to consumers, Canopy Growth delivers innovative products from owned and licensed brands including Tweed, 7ACRES, DOJA, Deep Space, Deelish, Claybourne, MTL Cannabis, Low Key by MTL and R'belle, as well as category defining vaporization devices by Storz & Bickel.


Canopy Growth is Canada’s leading provider of medical cannabis services. Through Canada House Clinics Inc., the Company operates clinics across Canada that work directly with primary care teams to provide specialized cannabinoid therapy services to patients suffering from simple and complex medical conditions. Abba Medix, Canopy Growth’s established online medical channel, serves as a leading distributor of medical cannabis in Canada, together expanding the Company’s ability to reach and support patients nationwide and internationally.


Canopy Growth has also established a comprehensive ecosystem to realize the opportunities presented by the U.S. THC market through an unconsolidated, non-controlling interest in Canopy USA. Canopy USA’s portfolio includes ownership of Acreage Holdings, Inc., a vertically integrated multi-state cannabis operator with operations throughout the U.S. Northeast and Midwest, as well as ownership of Wana Wellness, LLC, The Cima Group, LLC, and Mountain High Products, LLC, a leading North American edibles brand, and majority ownership of Lemurian, Inc., a California-based producer of high-quality cannabis extracts and clean vape technology.


At Canopy Growth, we’re shaping a future where cannabis is embraced for its potential to enhance well-being and improve lives. With high-quality products, a commitment to responsible use, and a focus on enhancing the communities where we live and work, we’re paving the way for a better understanding of all that cannabis can offer.


For more information visit www.canopygrowth.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260331523789/en/
Media: media@canopygrowth.com

Investor: invest@canopygrowth.com


Original: Canopy Growth Unveils New Brand ‘Deelish’: High THC, Everyday Price

Canopy Growth’s Apollo Cannabis Clinics Named Best Medical Cannabis ClinicMarch 30, 2026 7:30 AM
Business Wire
Voted best by Toronto Star Readers’ Choice Awards


Canopy Growth Corporation (“Canopy Growth” or the “Company”) (TSX: WEED) (Nasdaq: CGC) today announced that its Apollo Cannabis Clinics (“Apollo”) has been named Best Medical Cannabis Clinic in the 2025 Toronto Star’s Readers’ Choice Awards, a public vote that reflects the trust patients place in Apollo’s care.


Apollo represents the Company’s commitment to raising the standard of medical cannabis and making quality treatment accessible to every Canadian.


“This recognition comes directly from the people we care for, and that makes it especially meaningful,” said Luc Mongeau, Chief Executive Officer of Canopy Growth. “Everything Apollo does is grounded in genuine commitment to positive patient outcomes and our team works hard to make medical cannabis care accessible and supportive. To have that trusted by so many Canadians is something we don’t take lightly.”


Apollo provides Canada-wide access to free, fully virtual medical cannabis consultations – no referral required. Patients receive personalized treatment plans, ongoing education, and continuous support. To date, Apollo has helped thousands of Canadians manage chronic pain, anxiety, sleep disorders, PTSD, and other complex conditions through evidence-based care.


The annual Toronto Star’s Readers’ Choice Awards are determined entirely by public vote, with the public nominating and selecting the businesses they trust most across hundreds of categories.


About Canopy Growth


Canopy Growth is a world-leading cannabis company dedicated to unleashing the power of cannabis to improve lives.


Through an unwavering commitment to consumers, Canopy Growth delivers innovative products from owned and licensed brands including Tweed, 7ACRES, DOJA, Deep Space, Claybourne, MTL Cannabis, Low Key by MTL, and R'belle, as well as category defining vaporization devices by Storz & Bickel.


Canopy Growth is Canada’s leading provider of medical cannabis services. Through Canada House Clinics Inc., the Company operates clinics across Canada that work directly with primary care teams to provide specialized cannabinoid therapy services to patients suffering from simple and complex medical conditions. Abba Medix, Canopy Growth’s established online medical channel, serves as a leading distributor of medical cannabis in Canada, together expanding the Company’s ability to reach and support patients nationwide and internationally.


Canopy Growth has also established a comprehensive ecosystem to realize the opportunities presented by the U.S. THC market through an unconsolidated, non-controlling interest in Canopy USA. Canopy USA’s portfolio includes ownership of Acreage Holdings, Inc., a vertically integrated multi-state cannabis operator with operations throughout the U.S. Northeast and Midwest, as well as ownership of Wana Wellness, LLC, The Cima Group, LLC, and Mountain High Products, LLC, a leading North American edibles brand, and majority ownership of Lemurian, Inc., a California-based producer of high-quality cannabis extracts and clean vape technology.


At Canopy Growth, we’re shaping a future where cannabis is embraced for its potential to enhance well-being and improve lives. With high-quality products, a commitment to responsible use, and a focus on enhancing the communities where we live and work, we’re paving the way for a better understanding of all that cannabis can offer.


For more information visit www.canopygrowth.com.


About Apollo Cannabis Clinics


Apollo Cannabis Clinics is Canada's leading network of medical cannabis clinics, providing free, fully virtual care to patients across the country. Founded on a foundation of clinical research, Apollo connects Canadians with licensed healthcare practitioners for personalized, evidence-based medical cannabis treatment. Learn more at apollocannabis.ca.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260329350067/en/
Media: media@canopygrowth.com

Investor: invest@canopygrowth.com


Original: Canopy Growth’s Apollo Cannabis Clinics Named Best Medical Cannabis Clinic

Canopy Growth Announces Storz & Bickel Executive TransitionMarch 27, 2026 7:30 AM
Business Wire
David Männer appointed Managing Director


Jürgen Bickel, who co-founded and built Storz & Bickel into a global premium vaporization technology leader, passes the torch following 25 years of transformational leadership


Canopy Growth Corporation (“Canopy Growth” or the “Company”) (TSX: WEED) (Nasdaq: CGC) today announced the appointment of David Männer as Managing Director of Storz & Bickel, a subsidiary of Canopy Growth, effective April 1, 2026. Mr. Männer succeeds Jürgen Bickel, Storz & Bickel’s Co-founder, who has decided to transition out of his role.


Founded in 2001, Storz & Bickel has grown into a global leader in vaporization technology. Today, it sets the standard for innovation, product quality and design, earning recognition as the industry benchmark for vapor quality, the first ISO 13485 certification for medical-grade devices, and the prestigious Dr. Rudolf Eberle Prize for technical innovation.


“Storz & Bickel is the best in the world at what we do. We have built a global leader, a standard, and a culture that will be modelled for years to come. This is my legacy and I am thrilled to entrust its next chapter to someone I have complete confidence will carry it successfully into the future. I’ll be following along and cheering on what comes next,” said Jürgen Bickel, Storz & Bickel’s co-founder and outgoing Managing Director.


A 14-year veteran of Storz & Bickel, most recently serving as Deputy Managing Director, Mr. Männer brings deep operational knowledge, strong leadership, and an intimate understanding of what makes it exceptional.


“Jürgen has built a culture of product excellence, a discipline around standards, and a passionate team. It is on this foundation that I am excited to apply what I’ve learned and write the next chapter,” said David Männer, Incoming Managing Director, Storz & Bickel.


Luc Mongeau, Chief Executive Officer of Canopy Growth added, “Storz & Bickel is a global leader because of Jürgen's vision and relentless drive. We have a clear path forward – deepening our presence in the U.S. and pushing the pace of innovation. With David stepping into this role, we have exactly the right person to accelerate what's been built and take Storz to its next level of growth.”


About Canopy Growth


Canopy Growth is a world-leading cannabis company dedicated to unleashing the power of cannabis to improve lives.


Through an unwavering commitment to consumers, Canopy Growth delivers innovative products from owned and licensed brands including Tweed, 7ACRES, DOJA, Deep Space, and Claybourne, MTL Cannabis, Low Key by MTL and R'belle, as well as category defining vaporization devices by Storz & Bickel.


Canopy Growth is Canada’s leading provider of medical cannabis services. Through Canada House Clinics Inc., the Company operates clinics across Canada that work directly with primary care teams to provide specialized cannabinoid therapy services to patients suffering from simple and complex medical conditions. Abba Medix, Canopy Growth’s established online medical channel, serves as a leading distributor of medical cannabis in Canada, together expanding the Company’s ability to reach and support patients nationwide and internationally.


Canopy Growth has also established a comprehensive ecosystem to realize the opportunities presented by the U.S. THC market through an unconsolidated, non-controlling interest in Canopy USA. Canopy USA’s portfolio includes ownership of Acreage Holdings, Inc., a vertically integrated multi-state cannabis operator with operations throughout the U.S. Northeast and Midwest, as well as ownership of Wana Wellness, LLC, The Cima Group, LLC, and Mountain High Products, LLC, a leading North American edibles brand, and majority ownership of Lemurian, Inc., a California-based producer of high-quality cannabis extracts and clean vape technology.


At Canopy Growth, we’re shaping a future where cannabis is embraced for its potential to enhance well-being and improve lives. With high-quality products, a commitment to responsible use, and a focus on enhancing the communities where we live and work, we’re paving the way for a better understanding of all that cannabis can offer.


For more information visit www.canopygrowth.com.


About STORZ & BICKEL GmbH:


STORZ & BICKEL GmbH is the global leading manufacturer of high-end and medically certified cannabis vaporizers. With their commitment to quality, innovation, and compliance, the company has consistently delivered exceptional products that meet the highest industry standards. Based in Tuttlingen, Germany, STORZ & BICKEL continuously drives the advancement of vaporization technology, providing a safe and efficient means of consuming cannabis for medical purposes.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260326379084/en/
Media Contact: media@canopygrowth.com

Investor Contact: invest@canopygrowth.com


Original: Canopy Growth Announces Storz & Bickel Executive Transition

$CGC 🌿 All Canopy Growth (CGC) Products — Clean List Format
Tweed
Dried flower

Pre-rolls

Vapes (including CCELL AIO vapes)

Edibles

Beverages

Oils

Softgels

7ACRES
Premium dried flower

Pre-rolls (including medical-exclusive formats)

Vapes (live resin, liquid diamonds, AIO vapes)

DOJA
Premium dried flower

Deep Space
THC beverages

High-potency gummies

Ace Valley
THC beverages

Vert (Quebec-exclusive)
Dried flower (Green Cush, Sour Kush)

Twd.
Dried flower

Oils

Softgels

Wana
Gummies (various cannabinoid ratios and terpene profiles)

Hiway
Dried flower

Pre-rolls

PAX Era vape pods

LivRelief
CBD topicals

THC topicals

Mixed-cannabinoid creams

Spectrum Therapeutics (Medical)
Medical-grade dried flower

Medical pre-rolls

Oils

Softgels

Recent 2025 Launches
High-THC flower (28%+)

Infused pre-rolls

New CCELL AIO vapes

New Deep Space gummies

🏭 Cost-Cutting + Facility Optimization
CGC has closed inefficient facilities and consolidated operations, improving:

Gross margins

Cash burn

Long-term sustainability

This is critical for a turnaround story.

🧪 Product Innovation & Brand Strength
CGC continues to innovate in:

Solventless extracts

Live resin vapes

THC beverages

Medical formulations

Brand strength matters in a crowded market.

🇨🇦 Strong Canadian Market Share in Key Categories
CGC remains a top player in:

Vapes

Edibles

Beverages (THC drinks)

Premium flower

Its beverage segment (with Constellation Brands’ legacy influence) is one of the fastest-growing in Canada. $CGC $WEED

$WEED $CGC 🌿 U.S. Cannabis Legalization Momentum
CGC is one of the biggest potential winners if the U.S. moves forward with:

Federal rescheduling to Schedule III

SAFE Banking Act

State-level expansions (OH, PA, FL, etc.)

CGC already has a U.S. structure (Canopy USA) ready to activate once federal barriers ease.